Tipo de CambioTipo de Cambio
    Facebook Twitter Instagram
    Tendencias:
    • ¿Qué es ChatGPT y cómo funciona? ¿Qué la distingue a de otras herramientas de mensajería?
    • Biswap Ingresos pasivos y clave para funciones lucrativas
    • Liquidez, ¿Qué significa?, Liquidez vs Volumen
    • Carteras de Custodia, ¿Qué Son?, Ventajas, Desventajas
    • Sweatcoin rompe récord en venta pública en DAOMaker
    • Coinplay Crypto Casino Apuestas Deportivas
    Facebook Twitter Instagram
    Tipo de CambioTipo de Cambio
    Actualizar
    martes, marzo 7
    • Inicio
    • Dinero
    • Bitcoin
    • Ethereum
    • Binance
    • Criptomonedas
      • Solana
      • Cardano
    • Polkadot
    • Shiba Inu
    Tipo de CambioTipo de Cambio
    Formulario 6-K NOVO NORDISK A S para: 30 de junio
    Tipo de Cambio de Divisas

    Formulario 6-K NOVO NORDISK A S para: 30 de junio

    usdgbp_lwn506By usdgbp_lwn506agosto 5, 2021No hay comentarios1 Min Read
    StreetInsider.com
    Share
    Facebook Twitter LinkedIn Pinterest Email
    Rate this post


    Noticias e investigación antes de que se entere en CNBC y otros. Solicite su prueba gratuita de 1 semana para StreetInsider Premium aquí.


    ESTADOS UNIDOS

    COMISIÓN NACIONAL DEL MERCADO DE VALORES

    Washington, D.C.20549

    _________________________

    FORMULARIO 6-K

    _________________________

    INFORME DE EMISOR PRIVADO EXTRANJERO

    De conformidad con la regla 13a-16 o 15d-16

    de la Ley de Bolsa de Valores de 1934

    4 de agosto de 2021

    _________________________

    NOVO NORDISK A / S

    (Nombre exacto del Registrante como se especifica en su estatuto)

    _________________________

    Novo Allé

    DK-2880 Bagsværd

    Dinamarca

    (Dirección de las oficinas ejecutivas principales)

    Indique con una marca de verificación si el registrante presenta o presentará informes anuales al amparo del Formulario 20-F o el Formulario 40-F

    Formulario 20-F X Formulario 40-F o

    Indique con una marca de verificación si el registrante al proporcionar la información contenida en este Formulario también está proporcionando la información a la Comisión de conformidad con la Regla 12g3-2 (b) bajo la Ley de Bolsa de Valores de 1934.

    sí o No X

    Si se marca “Sí”, indique a continuación el número de archivo asignado al registrante en relación con la Regla 12g-32 (b): 82 -________

    Aspiraciones estratégicas Estado financiero Ejecución comercial Finanzas Flujo de caja y asignación de capital panorama Innovación y enfoque terapéutico Propósito y sustentabilidad Información financiera
    Anuncio de empresa no 48/2021

    newheader.jpg "src =" http://www.streetinsider.com/images/secattach/20210804/18768873_newheader.jpg "style =" height: 59px; margin-bottom: 5pt; vertical-align: text-bottom; width: 281px "/><span>                                         </span><img alt=

    Informe financiero para el período comprendido entre el 1 de enero de 2021 y el 30 de junio de 2021

    4 de agosto de 2021

    Aumento del beneficio neto de Novo Nordisk en un 10% en los primeros seis meses de 2021

    •El beneficio operativo disminuyó un 1% en coronas danesas y aumentó un 9% a tipos de cambio constantes (CER).

    •Las ventas aumentaron un 5% en coronas danesas y un 12% en CER a 66.800 millones de coronas danesas. Las ventas en operaciones internacionales aumentaron un 7% en coronas danesas (13% en CER) y las ventas en América del Norte aumentaron un 1% en coronas danesas (11% en CER).

    •Las ventas en el cuidado de la diabetes y la obesidad aumentaron un 5% en coronas danesas a 56.900 millones de coronas danesas (13% en CER), impulsadas por un crecimiento de GLP-1 del 21% en coronas danesas (30% en CER) que refleja la adopción de Ozempic® y Rybelsus®. El cuidado de la obesidad creció en un 23% en coronas danesas (34% en CER) aDakota del Norte Las ventas de productos biofarmacéuticos se mantuvieron sin cambios en coronas danesas (aumentaron un 7% en CER).

    •En junio de 2021, Wegovy ™, semaglutida 2,4 mg, se puso a disposición de los pacientes en los EE. UU. Tras la aprobación de la Administración de Drogas y Alimentos de los EE. UU. (FDA) para el control del peso en adultos que viven con obesidad.

    •Para la perspectiva de 2021, ahora se espera que el crecimiento de las ventas sea del 10 al 13% en CER (anteriormente, del 6 al 10%), y ahora se espera que el crecimiento de las ganancias operativas sea del 9 al 12% en el CER (anteriormente, del 5 al 9%). Se espera que el crecimiento de las ventas informado en coronas danesas sea 4 puntos porcentuales más bajo que en CER y ahora se espera que el crecimiento de las ganancias operativas informado en coronas danesas sea 5 puntos porcentuales más bajo que en CER.

    GANANCIA Y PERDIDA 1S 2021 Primer semestre de 2020 Crecimiento
    como se informó
    Crecimiento
    en CER *
    Millones de DKK
    Las ventas netas 66,845 63,881 5 % 12 %
    Beneficio operativo 29,761 30,140 (1 %) 9 %
    Beneficio neto 24,746 22,522 10 % N / A
    Beneficio por acción diluido (en DKK) 10,71 9.58 12 % N / A

    * CER: Tasas de cambio constantes (promedio 2020).

    Lars Fruergaard Jørgensen, presidente y director ejecutivo: "Estamos satisfechos con el crecimiento de las ventas en el primer semestre de 2021. El crecimiento está impulsado por todas las áreas geográficas dentro de las operaciones internacionales, así como por las operaciones de América del Norte, y por todas las áreas de terapia, en particular por nuestra cartera de tratamientos GLP-1. Dentro de I + D, alcanzamos un hito muy importante con la aprobación de Wegovy ™ en los EE. UU., ofreciendo a las personas que viven con obesidad una nueva opción de tratamiento eficaz. El sólido desempeño financiero en la primera mitad de 2021 y la sustancial demanda inicial de Wegovy ™ en los EE. UU. nos ha permitido elevar nuestras perspectivas para todo el año ".

    El 4 de agosto de 2021 a las 19.00 CEST, correspondiente a las 13.00 PM EDT, se llevará a cabo una llamada de resultados. Los inversores podrán escuchar a través de un enlace en novonordisk.com, que se puede encontrar en "Inversores".

    Novo Nordisk A / S

    Relaciones con inversionistas

    Novo Allé
    2880 Bagsværd
    Dinamarca
    Teléfono:
    +45 4444 8888
    www.novonordisk.com
    Número de CVR:
    24 25 67 90
    Anuncio de empresa no 48/2021

    Informe financiero para el período comprendido entre el 1 de enero de 2021 y el 30 de junio de 2021

    ASPIRACIONES ESTRATÉGICAS

    ASPIRACIONES ESTRATÉGICAS 2025

    Las aspiraciones estratégicas son objetivos en los que Novo Nordisk pretende trabajar y no son una proyección de las perspectivas financieras o el crecimiento esperado de Novo Nordisk. Novo Nordisk tiene la intención de describir cómo se desarrollan sus actividades en relación con cada una de las cuatro dimensiones de forma continua.

    Aspectos destacados del rendimiento para los primeros seis meses de 2021 (desarrollos del segundo trimestre):

    Propósito y sustentabilidad Innovación y enfoque terapéutico

    Añadiendo valor a la sociedad:

    •Progreso en la estrategia 'Derrotar a la diabetes':

    ◦Colaboración con la Universidad de Toronto centrada en la prevención

    ◦Iniciación de 'Diabetes Compass' por la Fundación Mundial de la Diabetes para mejorar el acceso a la atención diabética en países de ingresos bajos y medianos

    ◦Llegar a 15 países para cambiar la diabetes en los niños mediante la inclusión de Ghana

    ◦Lanzamiento de Prevention Accelerator que invita a las empresas emergentes a presentar ideas sobre cómo predecir o prevenir la obesidad

    Avances hacia el impacto ambiental cero:

    •45% de reducción de CO2 emisiones en comparación con los primeros seis meses de 2019

    •Aproximadamente un 15% de reducción en el CO2 del proveedor2 emisiones

    Desarrolle la cultura y garantice capacidades centrales distintas:

    •Lanzamiento de un objetivo ambicioso de diversidad de género

    Elevar aún más el listón de la innovación para el tratamiento de la diabetes:

    •Aprobación de Ozempic® en China para el tratamiento de la diabetes tipo 2

    •Reenvío de semaglutida 2,0 mg en EE. UU.

    •Inicio de la fase 2 con cagrilintida en combinación con semaglutida en personas con diabetes tipo 2

    Desarrollar soluciones de tratamiento superiores para la obesidad:

    •Decisión de iniciar el desarrollo de la fase 3a con 50 mg de semaglutida oral en la obesidad

    •Aprobación de Wegovy ™, semaglutida 2,4 mg, en EE. UU.

    Fortalecer y hacer progresar la cartera de productos biofarmacéuticos:

    •Sogroya®, somapacitan, aprobado en la UE para el tratamiento de adultos con deficiencia de hormona del crecimiento

    Establecer presencia en otras enfermedades crónicas graves:

    •Se inició el desarrollo de la fase 3a para el tratamiento de NASH y Enfermedad de Alzheimer con semaglutida

    •Nuevo acuerdo de licencia de I + D de células madre con Heartseed y adquisición del programa de amiloidosis ATTR de Prothena

    Ejecución comercial Finanzas

    Fortalecer el liderazgo en diabetes:

    •La cuota de mercado del valor de la diabetes aumentó en 0,5 puntos porcentuales hasta el 29,6% (MAT)

    Fortalecer el liderazgo en obesidad y la doble venta:

    •Las ventas de atención para la obesidad aumentaron un 34% (CER) a 3.500 millones de coronas danesas

    Asegurar una perspectiva de crecimiento sostenido para Biopharm:

    •Las ventas de productos biofarmacéuticos aumentaron un 7% (CER)

    Entregue ventas sólidas y crecimiento de las ganancias operativas:

    •Crecimiento de ventas al 12% (CER)

    •Crecimiento de ventas de operaciones internacionales del 13% (CER)

    •Crecimiento de las ventas en EE. UU. Del 10% con un 56% de las ventas provenientes de productos lanzados desde 2015

    •Crecimiento del beneficio operativo del 9% (CER)

    Impulse la eficiencia operativa:

    •Aumentos continuos de la productividad en el suministro de productos

    Permitir una asignación de capital atractiva para los accionistas:

    •El flujo de caja libre de DKK 32,7 mil millones y DKK 21,9 mil millones devuelto a los accionistas

    Aspiraciones estratégicas Aspectos destacados del rendimiento Ejecución comercial Finanzas Flujo de caja y asignación de capital panorama Innovación y enfoque terapéutico Propósito y sustentabilidad Información financiera
    Anuncio de empresa no 48/2021

    Informe financiero del período comprendido entre el 1 de enero de 2021 y el 30 de junio de 2021

    ASPECTOS DESTACADOS DEL RENDIMIENTO

    ASPECTOS FINANCIEROS DESTACADOS DE LOS PRIMEROS SEIS MESES DE 2021

    GANANCIA Y PERDIDA 1S 2021 Primer semestre de 2020 % de cambio H1 2021 a H1 2020 % de cambio H1 2021 a H1 2020 en CER
    (Las cantidades están en millones de DKK, excepto por el número de acciones, las ganancias por acción y los empleados)
    Las ventas netas 66,845 63,881 5 % 12 %
    Beneficio bruto 55,487 53,723 3 % 11 %
    Margen bruto 83,0% 84,1%
    Costos de ventas y distribución 16,257 14,988 8 % 15 %
    Porcentaje de ventas 24,3% 23,5%
    Costos de investigación y desarrollo 7.888 7.068 12 % 15 %
    Porcentaje de ventas 11,8% 11,1%
    Costes administrativos 1.836 1,754 5 % 8 %
    Porcentaje de ventas 2,7% 2,7%
    Otros ingresos operativos, neto 255 227 12 % 20 %
    Beneficio operativo 29,761 30,140 (1 %) 9 %
    Margen operativo 44,5% 47,2%
    Partidas financieras (neto) 1.094 (1.703) (164 %) N / A
    Beneficio antes de impuestos sobre la renta 30,855 28,437 9 % N / A
    Impuestos sobre la renta 6,109 5.915 3 % N / A
    Tasa efectiva de impuestos 19,8% 20,8%
    Beneficio neto 24,746 22,522 10 % N / A
    Margen de beneficio neto 37,0% 35,3%
    OTROS NÚMEROS CLAVE
    Depreciación, amortización y pérdidas por deterioro 2.594 2,244 dieciséis % N / A
    Gastos de capital 3,111 2.906 7 % N / A
    Efectivo neto generado por actividades operativas 36,510 34,273 7 % N / A
    Flujo de caja libre 32,696 30,335 8 % N / A
    Los activos totales 158,095 136,121 dieciséis % N / A
    Capital 65,559 60,054 9 % N / A
    Ratio de equidad 41,5% 44,1%
    Número medio de acciones diluidas en circulación (millones) 2.310,9 2.349,9 (2 %) N / A
    Beneficio diluido por acción / ADR (en DKK) 10,71 9.58 12 % N / A
    Empleados equivalentes a tiempo completo al final del período 45,971 43,526 6 % N / A

    Estos estados financieros consolidados no auditados para los primeros seis meses de 2021 se han preparado de acuerdo con la NIC 34 "Información financiera intermedia" y los requisitos de divulgación daneses adicionales para las empresas que cotizan en bolsa. Las políticas contables adoptadas en la preparación son consistentes con las aplicadas en el Informe Anual 2020 de Novo Nordisk.

    Aspiraciones estratégicas Aspectos destacados del rendimiento Ejecución comercial Finanzas Flujo de caja y asignación de capital panorama Innovación y enfoque terapéutico Propósito y sustentabilidad Información financiera
    Anuncio de empresa no 48/2021

    Informe financiero para el período comprendido entre el 1 de enero de 2021 y el 30 de junio de 2021

    EJECUCIÓN COMERCIAL

    DESARROLLO DE VENTAS EN TODAS LAS ÁREAS TERAPÉUTICAS

    Las ventas crecieron un 5% medido en coronas danesas y un 12% en CER los primeros seis meses de 2021, impulsadas por el crecimiento en todas las áreas de terapia con un crecimiento de las ventas de atención para la diabetes del 11% (CER), un crecimiento de las ventas de atención para la obesidad del 34% (CER ) y crecimiento de las ventas de Biopharm del 7% (CER). El crecimiento de las ventas se ve afectado positivamente por los cambios de inventario y el momento de los envíos en 2021. El crecimiento de las ventas en los primeros seis meses de 2020 se vio afectado positivamente por el almacenamiento relacionado con COVID-19, compensado en gran medida por un menor número de pacientes que iniciaron el tratamiento.

    Distribución de ventas por terapia Ventas 1S 2021
    Millones de DKK
    Ventas 1S 2020
    Millones de DKK
    Crecimiento
    como se informó
    Crecimiento
    en CER
    Participación del crecimiento
    en CER
    Segmento de atención a la diabetes y la obesidad

    Rybelsus®

    1,674 584 187 % 213 % 17 %

    Ozempic®

    14.097 9.591 47 % 58 % 75 %

    Victoza®

    7.606 9.225 (18 %) (12 %) (15 %)
    GLP-1 total 23,377 19.400 21 % 30 % 77 %
    Insulina de acción prolongada 8,971 9.378 (4 %) 2 % 2 %

    – Tresiba®

    4.557 4.618 (1 %) 5 % 3 %

    – Xultophy®

    1.326 1.238 7 % 12 % 2 %

    – Levemir®

    3,088 3,522 (12 %) (6 %) (3 %)
    Insulina premezclada 5.668 5.648 0 % 5 % 4 %

    – Ryzodeg®

    841 671 25 % 34 % 3 %

    – NovoMix®

    4.827 4.977 (3 %) 2 % 1 %
    Insulina de acción rápida 8.808 9.493 (7 %) (1 %) (2 %)

    – Fiasp®

    837 676 24 % 30 % 2 %

    – NovoRapid®

    7,971 8.817 (10 %) (4 %) (4 %)
    Insulina humana 4.576 5,001 (8 %) (3 %) (2 %)
    Insulina total 28.023 29,520 (5 %) 1 % 2 %

    Otro cuidado de la diabetes1

    1,919 2.102 (9 %) (5 %) (1 %)
    Cuidado total de la diabetes 53,319 51,022 5 % 11 % 78 %

    Cuidado de la obesidad (Saxenda® y Wegovy™)

    3,543 2,885 23 % 34 % 13 %
    Atención total de diabetes y obesidad 56,862 53,907 5 % 13 % 91 %
    Segmento biofarmacéutico

    Trastornos sanguíneos raros2

    5.401 5.211 4 % 11 % 7 %
    – Hemofilia A 1,120 845 33 % 39 % 4 %
    – Hemofilia B 309 247 25 % 30 % 1 %

    – NovoSeven®

    3.855 4,009 (4 %) 3 % 2 %

    Trastornos endocrinos raros3

    3,779 3.983 (5 %) 2 % 1 %

    Otros productos biofarmacéuticos4

    803 780 3 % 5 % 1 %
    Total biofarmacéutico 9,983 9,974 0 % 7 % 9 %
    Ventas totales 66,845 63,881 5 % 12 % 100 %

    1) Principalmente NovoNorm®, agujas y GlucaGen® HypoKit®.

    2) Incluye NovoSeven®, NovoEight®, Esperoct®, Refixia® y NovoThirteen®.

    3) Principalmente Norditropin®.

    4) Principalmente Vagifem® y Activelle®.

    Aspiraciones estratégicas Aspectos destacados del rendimiento Ejecución comercial Finanzas Flujo de caja y asignación de capital panorama Innovación y enfoque terapéutico Propósito y sustentabilidad Información financiera
    Anuncio de empresa no 48/2021

    Informe financiero para el período comprendido entre el 1 de enero de 2021 y el 30 de junio de 2021

    CUIDADO DE DIABETES Y OBESIDAD

    Cuidado de la diabetes, ventas y desarrollo de la cuota de mercado

    Las ventas en el cuidado de la diabetes aumentaron un 5% medido en coronas danesas y un 11% en CER a 53.319 millones de DKK impulsados ​​por el crecimiento de GLP-1. Novo Nordisk ha mejorado la cuota de mercado global del valor de la diabetes en los últimos 12 meses del 29,1% al 29,6% en línea con la aspiración de fortalecer el liderazgo en el cuidado de la diabetes, con el objetivo de alcanzar una cuota de mercado de valor global de más de un tercio en 2025. El El aumento de participación de mercado fue impulsado por ganancias de participación de mercado tanto en Operaciones Internacionales como en Operaciones de Norteamérica.

    En las siguientes secciones, a menos que se indique lo contrario, los datos de mercado se basan en el total anual móvil (MAT) de mayo de 2021 y mayo de 2020 proporcionado por el proveedor de datos independiente IQVIA. EMEA cubre Europa, Oriente Medio y África, la región de China cubre China continental, Hong Kong y Taiwán, y el resto del mundo cubre todos los demás países excepto Norteamérica.

    Atención de la diabetes, desarrollo por área geográfica Participación de Novo Nordisk en el mercado total de diabetes (valor, MAT) Cuidado de la diabetes, desarrollo de ventas
    Mayo Mayo Ventas 1S 2021
    Millones de DKK
    Crecimiento
    en CER
    2021 2020
    Global 29,6 % 29,1 % 53,319 11 %
    Operaciones internacionales 24,0 % 22,5 % 29.294 13 %
    – EMEA * 28,1 % 27,3 % 14,676 11 %
    – Región China ** 32,4 % 27,8 % 7.866 13 %
    – Resto del mundo *** 14.0 % 13,2 % 6.752 19 %
    Operaciones en Norteamérica 31,6 % 31,5 % 24,025 9 %
    – Los Estados Unidos 31,6 % 31,6 % 22,534 9 %

    Fuente: IQVIA, datos de mayo de 2021. * Los datos de EMEA están disponibles para los mercados europeos y siete mercados fuera de Europa que representan aproximadamente el 90% de las ventas de atención para la diabetes de Novo Nordisk en el área. ** Datos para China continental, excluidos Hong Kong y Taiwán. *** Datos para el resto del mundo disponibles para siete mercados que representan aproximadamente el 70% de las ventas totales de atención para la diabetes de Novo Nordisk en el área.

    Terapia con GLP-1 para la diabetes tipo 2

    Ventas de productos GLP-1 para la diabetes tipo 2 (Rybelsus®, Ozempic® y Victoza®) aumentó en un 21% medido en coronas danesas y en un 30% en CER a 23.377 millones de DKK. La participación de valor del segmento GLP-1 del mercado total de la diabetes ha aumentado al 24,0% en comparación con el 20,0% de hace 12 meses. Novo Nordisk sigue siendo el líder del mercado mundial en el segmento GLP-1 con una participación de mercado de valor del 51,5%, un aumento de 2,4 puntos porcentuales en comparación con hace 12 meses.

    GLP-1, desarrollo por área geográfica Participación de Novo Nordisk en el mercado de diabetes GLP-1 (valor, MAT) GLP-1, desarrollo de ventas
    Mayo Mayo Ventas 1S 2021
    Millones de DKK
    Crecimiento
    en CER
    2021 2020
    Global 51,5 % 49,1 % 23,377 30 %
    Operaciones internacionales 56,1 % 52,1 % 7.527 46 %
    – EMEA * 56,8 % 53,8 % 4.961 36 %
    – Región China ** 84,9 % 92,9 % 833 68 %
    – Resto del mundo *** 48,0 % 41,4 % 1,733 69 %
    Operaciones en Norteamérica 50,8 % 48,6 % 15,850 24 %
    – Los Estados Unidos 50,1 % 48,1 % 14,958 23 %

    Fuente: IQVIA, datos de mayo de 2021. * Los datos de EMEA están disponibles para los mercados europeos y siete mercados fuera de Europa que representan aproximadamente el 90% de las ventas de GLP-1 de Novo Nordisk en el área. ** Datos para China continental, excluidos Hong Kong y Taiwán. *** Datos para el resto del mundo disponibles para siete mercados que representan aproximadamente el 70% de las ventas totales de atención para la diabetes de Novo Nordisk en el área.

    Rybelsus® las ventas aumentaron en un 187%, medidas en coronas danesas, y en un 213% en CER, hasta los 1.674 millones de DKK. El crecimiento de las ventas fue impulsado por las operaciones de América del Norte, así como por EMEA y el resto del mundo. Rybelsus® ahora se ha lanzado en 18 países.

    Ozempic® las ventas aumentaron en un 47%, medidas en coronas danesas, y un 58% en CER, a 14.097 millones de DKK. El crecimiento de las ventas fue impulsado tanto por las operaciones en América del Norte como por las operaciones internacionales. Ozempic® ahora se ha lanzado en 62 países.

    Victoza® las ventas disminuyeron en un 18%, medidas en coronas danesas, y en un 12% en CER, hasta los 7.606 millones de coronas danesas. La caída de las ventas fue impulsada por las operaciones de América del Norte y EMEA, parcialmente compensadas por mayores ventas en la región de China y el resto del mundo.

    Aspiraciones estratégicas Aspectos destacados del rendimiento Ejecución comercial Finanzas Flujo de caja y asignación de capital panorama Innovación y enfoque terapéutico Propósito y sustentabilidad Información financiera
    Anuncio de empresa no 48/2021

    Informe financiero para el período comprendido entre el 1 de enero de 2021 y el 30 de junio de 2021

    Operaciones internacionales

    Las ventas de productos para la diabetes GLP-1 en Operaciones Internacionales aumentaron en un 40% medido en coronas danesas y en un 46% en CER. El crecimiento de las ventas está impulsado por todas las áreas geográficas. La participación en el valor de la clase GLP-1 del mercado total de diabetes ha aumentado al 11,9% desde el 9,8% de hace 12 meses. Novo Nordisk es el líder del mercado con una cuota de mercado de valor del 56,1%.

    EMEA

    Las ventas en EMEA aumentaron un 34% medido en coronas danesas y un 36% en CER. El crecimiento de las ventas refleja la adopción de Ozempic® y Rybelsus®, parcialmente compensado por menores ventas de Victoza®. Rybelsus® ahora se ha lanzado en 15 países de EMEA. Novo Nordisk sigue siendo el líder del mercado en EMEA con una cuota de mercado de valor del 56,8%.

    Región China

    Las ventas en la Región China aumentaron en un 66% medido en coronas danesas y un 68% en CER. El crecimiento de las ventas refleja la adopción de Victoza® en China continental y el lanzamiento de Ozempic® en Taiwan®. La participación de la clase GLP-1 en el valor general de mercado de la diabetes en la región de China aumentó a 4.1% desde 2.3% hace 12 meses con Victoza® cuota de mercado del 88,6%.

    Resto del mundo

    Las ventas en el resto del mundo aumentaron en un 51% medido en coronas danesas y en un 69% en CER. El crecimiento de las ventas refleja el aumento de las ventas de Ozempic® , Rybelsus®, tras el lanzamiento en Japón, y Victoza®. Novo Nordisk sigue siendo el líder del mercado con una cuota de mercado de valor del 48,0%.

    Operaciones en Norteamérica

    Las ventas de productos para la diabetes GLP-1 en América del Norte Las operaciones aumentaron un 13% medido en coronas danesas y un 24% en CER. Novo Nordisk es el líder del mercado con una cuota de mercado del 50,8% en valor en comparación con el 48,6% de hace 12 meses. La cuota de mercado de valor de la clase GLP-1 del mercado total de diabetes de América del Norte ha aumentado al 28,4% en comparación con el 23,8% de hace 12 meses.

    El crecimiento de las ventas en los EE. UU. Está impulsado por un crecimiento del volumen de prescripción de la clase GLP-1 de around 25% respecto al primer semestre de 2020. Rybelsus® la cuota de mercado semanal de nuevas marcas es 12,9%. La cuota de mercado combinada de medicamentos recetados nuevos para la marca Novo Nordisk GLP-1 es ahora del 62,6%. Novo Nordisk es el mlíder del mercado con un 51,3% medido sobre el total de recetas mensuales para la cartera combinada de GLP-1.

    Las ventas de GLP-1 en EE. UU. Aumentaron un 23% a CER. El aumento de las ventas fue impulsado por la adopción continua de Ozempic® y Rybelsus®, parcialmente compensado por la disminución de Victoza® Ventas. El crecimiento de las ventas de GLP-1 se vio afectado negativamente por las mejoras en los reembolsos, así como por la mezcla desfavorable de canales y pagadores.

    Aspiraciones estratégicas Aspectos destacados del rendimiento Ejecución comercial Finanzas Flujo de caja y asignación de capital panorama Innovación y enfoque terapéutico Propósito y sustentabilidad Información financiera
    Anuncio de empresa no 48/2021

    Informe financiero para el período comprendido entre el 1 de enero de 2021 y el 30 de junio de 2021

    Insulina

    Las ventas de insulina disminuyeron un 5%, medidas en coronas danesas, y aumentaron un 1% en CER a 28.023 millones de coronas danesas. El crecimiento de las ventas en CER fue impulsado por el aumento de las ventas en las operaciones internacionales, parcialmente compensado por la disminución de las ventas en los EE. UU.

    Insulina, desarrollo por área geográfica Participación de Novo Nordisk en el mercado total de insulina (volumen, MAT) Insulina, desarrollo de ventas
    Mayo Mayo Ventas 1S 2021
    Millones de DKK
    Crecimiento
    en CER
    2021 2020
    Global 47,3 % 47,0 % 28.023 1 %
    Operaciones internacionales 50,3 % 49,7 % 20,340 6 %
    – EMEA * 47,6 % 47,1 % 9.362 2 %
    – Región China ** 50,8 % 50,4 % 6.199 10 %
    – Resto del mundo *** 57,2 % 56,9 % 4.779 10 %
    Operaciones en Norteamérica 39,2 % 39,7 % 7.683 (11 %)
    – Los Estados Unidos 38,9 % 39,7 % 7.154 (11 %)

    Fuente: IQVIA, datos de mayo de 2021. * Los datos de EMEA están disponibles para los mercados europeos y siete mercados fuera de Europa que representan aproximadamente el 90% de las ventas de insulina de Novo Nordisk en el área. ** Datos para China continental, excluidos Hong Kong y Taiwán. *** Datos para el resto del mundo disponibles para siete mercados que representan aproximadamente el 70% de las ventas totales de atención para la diabetes de Novo Nordisk en el área.

    Operaciones internacionales

    Las ventas de insulina en Operaciones Internacionales aumentaron un 1% medido en coronas danesas y un 6% en CER. El crecimiento de las ventas en CER fue impulsado por la insulina de acción prolongada, la insulina premezclada y la insulina de acción rápida, parcialmente contrarrestadas por la insulina humana.

    EMEA

    Las ventas de insulina en EMEA disminuyeron un 3% medido en coronas danesas y aumentaron un 2% en CER. El crecimiento de las ventas en CER fue impulsado principalmente por Tresiba® y Fiasp®. Novo Nordisk tiene una cuota de mercado de volumen del 47,6% del mercado total de insulina.

    Región China

    Las ventas de insulina en la Región China aumentaron un 8% medido en coronas danesas y un 10% en CER. El crecimiento de las ventas fue impulsado por Tresiba®, NovoMix®, NovoRapid® y Ryzodeg®, parcialmente contrarrestado por insulina humana y Levemir®. Novo Nordisk tiene una cuota de mercado de volumen del 50,8% del mercado total de insulina.

    Resto del mundo

    Las ventas de insulina en el resto del mundo se mantuvieron sin cambios en coronas danesas y aumentaron un 10% en CER. El crecimiento de las ventas en CER fue impulsado por todos los productos de insulina excepto Levemir® y NovoMix®. Novo Nordisk tiene una cuota de mercado de volumen del 57,2% del mercado total de insulina.

    Operaciones en Norteamérica

    Las ventas de insulina en las operaciones de América del Norte disminuyeron un 18% medido en coronas danesas y un 11% en CER. The sales decrease in the US was driven by lower realised prices due to channel and payer mix and rebate enhancements as well as a decline in volume. Novo Nordisk has a volume market share of 39.2% of the total insulin market.

    Strategic aspirations Performance highlights Commercial execution Financials Cash flow and capital allocation Outlook Innovation and therapeutic focus Purpose and sustainability Financial Information
    Company announcement No 48 / 2021

    Financial report for the period 1 January 2021 to 30 June 2021

    Obesity care, sales development

    Sales of Obesity care products, Saxenda® and Wegovy™, increased by 23% measured in Danish kroner and by 34% at CER to DKK 3,543 million. Sales growth was driven by International Operations and North America Operations. Saxenda® has been launched in 58 countries and Wegovy™ was launched in the US in June 2021. Novo Nordisk currently has a value market share of 66.9% of the global branded obesity prescription drug market. The strategic aspiration for Obesity care is to more than double reported sales from the base in 2019 of DKK 5,679 million by 2025.

    Obesity care, development per geographical area Obesity care, sales development
    Sales H1 2021
    DKK million
    Crecimiento
    at CER
    Global 3,543 34 %
    International Operations 1,497 44 %
    – EMEA 839 55 %
    – Region China dieciséis –
    – Rest of World 642 30 %
    North America Operations 2,046 27 %
    – The US 1,874 27 %

    International Operations

    Sales of Saxenda® in International Operations increased by 33% measured in Danish kroner and by 44% at CER, driven by increased sales in EMEA and Rest of World. Novo Nordisk currently has a value market share of 42.8% in the branded obesity prescription drug market.

    EMEA

    Sales of Saxenda® in EMEA increased by 46% measured in Danish kroner and by 55% at CER. Novo Nordisk currently has a value market share of 67.3% in the branded obesity prescription drug market.

    Rest of World

    Sales of Saxenda® in Rest of World increased by 18% measured in Danish kroner and by 30% at CER. Saxenda® has been launched in 19 countries in Rest of World. Novo Nordisk currently has a value market share of 33.5% in the branded obesity prescription drug market.

    North America Operations

    Sales of Obesity care products in North America Operations increased by 16% measured in Danish kroner and by 27% at CER. Novo Nordisk now has a value market share of 83.0% in the obesity prescription drug market in North America. Wegovy™ was made available to patients in June 2021 and market access has progressed. The initial feedback from patients and prescribers has been encouraging. Initial demand has exceeded supply of Wegovy™ and patients may temporarily experience a delay in getting prescriptions filled.

    Strategic aspirations Performance highlights Commercial execution Financials Cash flow and capital allocation Outlook Innovation and therapeutic focus Purpose and sustainability Financial Information
    Company announcement No 48 / 2021

    Financial report for the period 1 January 2021 to 30 June 2021

    BIOPHARM

    Biopharm, sales development

    Sales of biopharm products remained unchanged in Danish kroner and increased by 7% at CER to DKK 9,983 million in line with the strategic aspiration of sustained growth in Biopharm. The sales growth at CER was driven by both North America Operations and International Operations. Sales growth was driven by both Rare blood disorders and Rare endocrine disorders.

    Biopharm, development per geographical area Biopharm, sales development
    Sales H1 2021
    DKK million
    Crecimiento
    at CER
    Global 9,983 7 %
    International Operations 6,193 4 %
    – EMEA 3,594 5 %
    – Region China 170 (30 %)
    – Rest of World 2,429 5 %
    North America Operations 3,790 12 %
    – The US 3,518 13 %

    Rare blood disorders

    Sales of rare blood disorder products increased by 4% measured in Danish kroner and by 11% at CER to DKK 5,401 million. The increasing sales were driven by the launch products Esperoct® and Refixia® as well as NovoEight® and NovoSeven®.

    Sales of haemophilia A products increased by 33% measured in Danish kroner and by 39% at CER to DKK 1,120 million. The sales increase was driven by both International Operations and North America Operations. Esperoct® has now been launched 21 countries.

    Sales of haemophilia B products increased by 25% measured in Danish kroner and by 30% at CER to DKK 309 million. The sales increase was driven by both International Operations and North America Operations. Refixia® has now been launched in 20 countries.

    Sales of NovoSeven® decreased by 4% measured in Danish kroner and increased by 3% at CER to DKK 3,855 million. The sales development was driven by increasing sales in North America Operations, partially offset by declining sales in International Operations. The sales decline in Region China reflects increased distributor stock levels in the first six months of 2020.

    Rare endocrine disorders

    Sales of rare endocrine disorder products decreased by 5% measured in Danish kroner and increased by 2% at CER to DKK 3,779 million driven by Norditropin®. The sales growth at CER was driven by International Operations increasing by 4% at CER, partially offset by North America Operations decreasing by 2%. Novo Nordisk is the leading company in the global human growth disorder market with a value market share of 35.9% compared to 34.3% a year ago, driven by new indications and the global roll-out of the next-generation device.

    Strategic aspirations Performance highlights Commercial execution Financials Cash flow and capital allocation Outlook Innovation and therapeutic focus Purpose and sustainability Financial Information
    Company announcement No 48 / 2021

    Financial report for the period 1 January 2021 to 30 June 2021

    FINANCIALS

    GEOGRAPHIC SALES DEVELOPMENT

    Sales increased by 5% measured in Danish kroner and by 12% at CER to DKK 66,845 million in the first six months of 2021. Sales in International Operations increased by 7% measured in Danish kroner and by 13% at CER. The strategic aspiration for International Operations is sales growth between 6-10%. Sales in North America Operations increased by 1% measured in Danish kroner and by 11% at CER. The strategic aspiration of transforming 70% of sales in the US has progressed, and 56% of sales are now derived from products launched since 2015.

    Sales split per geographical area Sales H1 2021
    DKK million
    Crecimiento
    as reported
    Crecimiento
    at CER
    Share of growth
    at CER
    International Operations 36,984 7 % 13 % 58 %
    – EMEA 19,109 7 % 11 % 27 %
    – Region China 8,052 10 % 12 % 11 %
    – Rest of World 9,823 6 % dieciséis % 20 %
    North America Operations 29,861 1 % 11 % 42 %
    – The US 27,926 0 % 10 % 39 %
    Total sales 66,845 5 % 12 % 100 %

    International Operations

    Sales in International Operations increased by 7% measured in Danish kroner and by 13% at CER. Sales growth was driven by all therapy areas with GLP-1 sales growing by 46% (CER), insulin sales growing by 6% (CER), Obesity care sales growing by 44% (CER) and Biopharm sales growing by 4% (CER).

    EMEA

    Sales in EMEA increased by 7% measured in Danish kroner and by 11% at CER. Sales growth was driven by Diabetes care growing by 11% (CER) driven by increased GLP-1 sales. Biopharm sales increased by 5% (CER) and Obesity care increased by 55% (CER).

    Region China

    Sales in Region China increased by 10% measured in Danish kroner and by 12% at CER. Sales growth was driven by Diabetes care growth of 13% (CER) reflecting increased insulin and GLP-1 sales, partially offset by Biopharm declining by 30% (CER) reflecting increased distributor stock levels in the first six months of 2020.

    Rest of World

    Sales in Rest of World increased by 6% measured in Danish kroner and by 16% at CER. Sales growth was driven by Diabetes care growing by 19% (CER), reflecting increased GLP-1 and insulin sales, Obesity care growing by 30% (CER) and Biopharm growing by 5% (CER).

    North America Operations

    Sales in North America Operations increased by 1% measured in Danish kroner and by 11% at CER. Sales growth was positively impacted by inventory changes in 2021.

    The sales increase reflects GLP-1 sales growing by 24% (CER), Obesity care growing by 27% (CER) and Biopharm sales growing by 12% (CER). This was partially offset by insulin sales decreasing by 11% (CER) driven by lower realised prices due to channel and payer mix and rebate enhancements as well as a decline in volume.

    Strategic aspirations Performance highlights Commercial execution Financials Cash flow and capital allocation Outlook Innovation and therapeutic focus Purpose and sustainability Financial Information
    Company announcement No 48 / 2021

    Financial report for the period 1 January 2021 to 30 June 2021

    DEVELOPMENT IN COSTS AND OPERATING PROFIT

    El cost of goods sold increased by 12% measured in Danish kroner and by 14% at CER to DKK 11,358 million, resulting in a gross margin of 83.0% measured in Danish kroner compared with 84.1% in 2020. The decline in gross margin reflects lower realised prices in the US, a negative currency impact of 0.7% percentage point and amortisation of intangible assets related to the acquisition of Emisphere Technologies Inc. in 2020. This is countered by a positive product mix driven by increased GLP-1 sales and productivity improvements in line with the strategic aspiration of driving operational efficiencies.

    Sales and distribution costs increased by 8% measured in Danish kroner and by 15% at CER to DKK 16,257 million. The increase in costs is driven by both International Operations and North America Operations. In International Operations, promotional spend is related to launch activities for Rybelsus® and Ozempic®, field force expansion in China as well as Obesity care market development activities. In North America Operations, the cost increase is driven by promotional activities for Rybelsus® and Ozempic®, partially offset by lower promotional spend related to insulin. The cost increase was impacted by low activity level in the second quarter of 2020 due to COVID-19.

    Research and development costs increased by 12% measured in Danish kroner and by 15% at CER to DKK 7,888 million. Increased activities within Other serious chronic diseases are driving the cost increase reflecting the progression of the pipeline within cardiovascular disease and NASH as well as increased costs within Obesity care driven by the ongoing cardiovascular outcomes trials, SOUL and SELECT. The cost increase was impacted by low activity level in the second quarter of 2020 due to COVID-19.

    Administration costs increased by 5% measured in Danish kroner and by 8% at CER to DKK 1,836 million, reflecting low spend in the second quarter of 2020 due to COVID-19 impact on activities.

    Other operating income (net) was DKK 255 million compared with DKK 227 million in the first six months of 2020.

    Operating profit decreased by 1% measured in Danish kroner and increased by 9% at CER to DKK 29,761 million.

    Financial items (net) showed a net gain of DKK 1,094 million compared with a net loss of DKK 1,703 million in the first six months of 2020.

    In line with Novo Nordisk’s treasury policy, the most significant foreign exchange risks for Novo Nordisk have been hedged, primarily through foreign exchange forward contracts. The foreign exchange result was a net gain of DKK 1,049 million compared with a net loss of DKK 1,555 million in the first six months of 2020. This reflects gains on hedged currencies, primarily the US dollar.

    As per the end of June 2021, a negative market value of financial contracts of approximately DKK 0.4 billion has been deferred for recognition later in 2021 and 2022.

    The effective tax rate is 19.8% in the first six months of 2021 compared with an effective tax rate of 20.8% in the first six months of 2020, reflecting favourable changes to tax positions covering prior years.

    Net profit increased by 10% to DKK 24,746 million and diluted earnings per share increased by 12% to 10.71 DKK.

    Strategic aspirations Performance highlights Commercial execution Financials Cash flow and capital allocation Outlook Innovation and therapeutic focus Purpose and sustainability Financial Information
    Company announcement No 48 / 2021

    Financial report for the period 1 January 2021 to 30 June 2021

    KEY DEVELOPMENTS IN THE SECOND QUARTER OF 2021

    Sales in the second quarter of 2021 increased by 10% measured in Danish kroner and by 17% at CER compared to the same period in 2020. Operating profit increased by 7% measured in Danish kroner and by 16% at CER. The results in Danish kroner were negatively impacted by the depreciation of the US dollar versus the Danish krone by 9%.

    Please refer to appendix 1 for an overview of the quarterly numbers in DKK and to appendix 6 for additional details on sales in the second quarter of 2021.

    Sales split per geographical area Sales Q2 2021
    DKK million
    Crecimiento
    as reported
    Crecimiento
    at CER
    Share of growth
    at CER
    International Operations 18,237 13 % 17 % 55 %
    – EMEA 9,579 17 % 20 % 34 %
    – Region China 3,722 7 % 7 % 5 %
    – Rest of World 4,936 10 % 18 % dieciséis %
    North America Operations 14,804 7 % dieciséis % 45 %
    – The US 13,754 6 % dieciséis % 42 %
    Total sales 33,041 10 % 17 % 100 %

    The increased global sales of 17% (CER) were driven by Diabetes and Obesity care sales as GLP-1 sales increased by 37% (CER), Obesity care sales increased by 63% and insulin sales increased by 1%. Biopharm sales increased by 13% (CER). Sales growth is positively impacted by COVID-19-related destocking and fewer patients initiating treatment in the second quarter of 2020 as well as inventory changes and timing of shipments in 2021.

    International Operations

    Sales in International Operations increased by 13% measured in Danish kroner and by 17% at CER. Sales growth was driven by all geographical areas. COVID-19-related destocking and fewer patients initiating treatment in the second quarter of 2020 positively impacted sales growth. Furthermore, sales growth is positively impacted by timing of shipments in the second quarter of 2021.

    Sales growth was driven by Diabetes and Obesity care growing by 19% (CER) driven by increased GLP-1 sales growing by 62% (CER), insulin sales growing by 7% (CER) and Obesity care increasing by 83% (CER). Biopharm sales increased by 8% (CER).

    North America Operations

    Sales in North America Operations increased by 7% measured in Danish kroner and by 16% at CER. COVID-19-related destocking and fewer patients initiating treatment in the second quarter of 2020 positively impacted sales growth.

    Sales growth was driven by GLP-1 growing by 28% (CER) reflecting the prescription volume growth, the uptake of Ozempic® and the launch of Rybelsus®. Insulin sales decreased by 11% (CER) driven by lower realised prices. Obesity care sales increased by 53% (CER) reflecting uptake of Saxenda® and the launch of Wegovy™ in June 2021. Biopharm sales increased by 21% (CER) driven by increased NovoSeven® sales, partially offset by lower Norditropin® sales.

    Strategic aspirations Performance highlights Commercial execution Financials Cash flow and capital allocation Outlook Innovation and therapeutic focus Purpose and sustainability Financial Information
    Company announcement No 48 / 2021

    Financial report for the period 1 January 2021 to 30 June 2021
    PROFIT AND LOSS Q2 2021 Q2 2020 % change Q2 2021 to Q2 2020 % change Q2 2021 to Q2 2020 at CER
    Las ventas netas 33,041 30,006 10 % 17 %
    Gross profit 27,494 25,234 9 % dieciséis %
    Gross margin 83.2% 84.1%
    Sales and distribution costs 8,001 7,398 8 % 15 %
    Percentage of sales 24.2% 24.7%
    Research and development costs 3,944 3,291 20 % 23 %
    Percentage of sales 11.9% 11.0%
    Administrative costs 904 827 9 % 14 %
    Percentage of sales 2.7% 2.8%
    Other operating income, net 134 120 12 % 21 %
    Operating profit 14,779 13,838 7 % dieciséis %
    Operating margin 44.7% 46.1%
    Financial items (net) 138 (422) (133 %) N / A
    Profit before income taxes 14,917 13,416 11 % N / A
    Income taxes 2,794 2,791 0 % N / A
    Effective tax rate 18.7% 20.8%
    Beneficio neto 12,123 10,625 14 % N / A
    Net profit margin 36.7% 35.4%

    Costs and operating profit

    The gross margin was 83.2% in the second quarter of 2021 compared with 84.1% in the same period last year. The 0.9 percentage point gross margin decline reflects lower realised prices in the US and a negative currency impact of 0.7 percentage point, partially countered by positive product mix.

    Sales and distribution costs increased by 8% measured in Danish kroner and by 15% at CER compared with the same period in 2020. The increase was driven by International Operations and North America Operations reflecting the launches of Rybelsus® and promotional activities related to Ozempic®. The cost increase was impacted by low activity level in the second quarter of 2020 due to COVID-19.

    Research and development costs increased by 20% measured in Danish kroner and by 23% at CER compared with the same period in 2020. The cost increase is reflecting low activity level in the second quarter of 2020 due to COVID-19.

    Administrative costs increased by 9% measured in Danish kroner and by 14% at CER compared with the same period in 2020. The cost increase is reflecting low activity level in the second quarter of 2020 due to COVID-19.

    Other operating income (net) of DKK 134 million in the second quarter of 2021 compared with DKK 120 million in the same period last year.

    Operating profit increased by 7% measured in Danish kroner and by 16% at CER compared with the same period in 2020.

    Financial items (net) showed a net gain of DKK 138 million compared with a net loss of DKK 422 million in the second quarter of 2020, mainly reflecting gains associated with foreign exchange hedging contracts, primarily related to the US dollar versus the Danish krone.

    Net profit increased by 14% to DKK 12,123 million and diluted earnings per share increased by 16% to 5.26 DKK.

    Strategic aspirations Performance highlights Commercial execution Financials Cash flow and capital allocation Outlook Innovation and therapeutic focus Purpose and sustainability Financial Information
    Company announcement No 48 / 2021

    Financial report for the period 1 January 2021 to 30 June 2021

    CASH FLOW AND CAPITAL ALLOCATION

    CAPITAL EXPENDITURE AND FREE CASH FLOW IN THE FIRST SIX MONTHS OF 2021

    Capital expenditure for property, plant and equipment was DKK 3.1 billion compared with DKK 2.9 billion in 2020.

    Free cash flow was DKK 32.7 billion compared with DKK 30.3 billion in 2020 supporting the strategic aspiration to deliver attractive capital allocation to shareholders. The increase reflects higher net profit and a favourable impact from change in working capital. The free cash is positively impacted by within-year-timing of rebate payments in the US.

    Novo Nordisk’s financial reserves were DKK 38.2 billion by end of June 2021 comprising cash at bank, marketable securities (measured at fair value based on active market data) and undrawn credit facilities less overdrafts and loans repayable within 12 months.

    EQUITY AND CAPITAL ALLOCATION

    Total equity was DKK 65,559 million at the end of the first six months of 2021, equivalent to 41.5% of total assets, compared with 44.1% at the end of the first six months of 2020. Please refer to appendix 5 for further elaboration of changes in equity.

    Interim dividend

    The Board of Directors has decided to pay out interim dividend for 2021 of DKK 3.50 for each Novo Nordisk A and B

    share of DKK 0.20, which will be paid in August 2021. The ex-dividend date for the interim dividend will be 16

    August 2021. The record date will be 17 August 2021 for the A and B shares as well as the ADRs. The payment date

    for the A and B shares will be 18 August 2021, while the payment date for the ADRs will be 25 August 2021. No

    dividend will be paid on the company’s holding of B shares.

    2021 share repurchase programme

    On 7 May 2021, Novo Nordisk announced a share repurchase programme of up to DKK 3.3 billion to be executed

    from 10 May to 3 August 2021, as part of an overall programme of up to DKK 18 billion to be executed during a 12-

    month period beginning 3 February 2021. The purpose of the programme was to reduce the company’s share capital

    and to meet obligations arising from share-based incentive programmes. Under the programme, Novo Nordisk has

    repurchased 6,349,637 B shares for an amount of DKK 3.3 billion in the period from 10 May to 3 August 2021. The

    programme was concluded on 3 August 2021.

    As of 3 August 2021, Novo Nordisk A/S has repurchased a total of 18,714,414 B shares equal to a transaction value

    of DKK 8.886 billion under the DKK 18 billion programme beginning 3 February 2021.

    As of 3 August 2021, Novo Nordisk and its wholly-owned affiliates owned 17,552,912 of its own B shares,

    corresponding to 0.8% of the total share capital.

    The execution of Novo Nordisk’s 2021 share repurchase programme of DKK 18 billion to be executed during a 12-

    month period beginning 3 February 2021 continues, and a new share repurchase programme will be initiated in

    accordance with Article 5 of Regulation No 596/2014 of the European Parliament and Council of 16 April 2014

    (MAR) and the Commission Delegated Regulation (EU) 2016/1052 of 8 March 2016 (the "Safe Harbour Rules”). For

    that purpose, Novo Nordisk A/S has appointed Skandinaviska Enskilda Banken, Danmark, filial af Skandinaviska Enskilda Banken AB (SEB), as lead manager to execute the programme independently and without influence from Novo Nordisk A/S. The purpose of the programme is to reduce the company’s share capital and to meet obligations arising from share-based incentive programmes. Under the agreement, SEB will repurchase B shares on behalf of Novo Nordisk A/S during the trading period starting today, 5 August, and ending on 1 November 2021.

    A maximum of 190,000,000 B shares in total can be bought during the trading period. The maximum number of B

    shares that can be repurchased on a single trading day may not exceed 20% of the average daily trading volume of

    Novo Nordisk B shares on the trading venue, on which the purchase takes place, during the preceding 20 trading

    days of the purchase (excluding the day of the purchase), cf Article 3(3) of the Commission Delegated Regulation

    (EU) 2016/1052. At least once every seven trading days, Novo Nordisk A/S will issue an announcement in respect of

    the transactions made under the repurchase programme.

    Strategic aspirations Performance highlights Commercial execution Financials Cash flow and capital allocation Outlook Innovation and therapeutic focus Purpose and sustainability Financial Information
    Company announcement No 48 / 2021

    Financial report for the period 1 January 2021 to 30 June 2021

    As announced in February 2021, Novo Nordisk’s majority shareholder Novo Holdings A/S, a holding company fully

    owned by the Novo Nordisk Foundation, has informed Novo Nordisk that it intends to consider its participation in

    the Novo Nordisk share repurchase programme on a year-by-year basis. For 2021, Novo Nordisk has been informed

    by Novo Holdings A/S that it plans to participate in the share repurchase programme. Novo Holdings A/S has an

    ownership of 28.3% of the Novo Nordisk share capital, and Novo Holdings A/S currently intends to maintain its

    ownership of the Novo Nordisk share capital around 28%.

    Issuance of Eurobonds

    On 27 May 2021, Novo Nordisk announced the successful Eurobond issuance in an aggregate principal amount of EUR 1.3 billion under its EUR 5 billion Euro Medium Term Note Programme. The first tranche maturing on 4 June 2024 was issued in an aggregate principal amount of EUR 650 million with a coupon of 0%. The second tranche maturing on 4 June 2028 was issued in an aggregate principal amount of EUR 650 million with a coupon of 0.125%. Net proceeds of the issuances will be used by Novo Nordisk for general corporate purposes. Further, part of the net proceeds have been used for refinancing of the bridge loan facility established in connection with Novo Nordisk’s acquisition of Emisphere Technologies Inc. in 2020. The bonds are recognised as borrowings measured at amortised cost.

    Strategic aspirations Performance highlights Commercial execution Financials Cash flow and capital allocation Outlook Innovation and therapeutic focus Purpose and sustainability Financial Information
    Company announcement No 48 / 2021

    Financial report for the period 1 January 2021 to 30 June 2021

    OUTLOOK

    OUTLOOK 2021

    The current expectations for 2021 are summarised in the table below:

    Expectations are as reported, if not otherwise stated Expectations
    4 August 2021
    Expectations
    5 May 2021
    Sales growth
    at CER 10% to 13% 6% to 10%
    as reported Around 4 percentage points lower than at CER Around 4 percentage points lower than at CER
    Operating profit growth
    at CER 9% to 12% 5% to 9%
    as reported Around 5 percentage points lower than at CER Around 6 percentage points lower than at CER
    Financial items (net) Gain of around DKK 0.6 billion Gain of around DKK 0.7 billion
    Effective tax rate 19% to 21% 20% to 22%
    Capital expenditure (PP&E) Around DKK 7.5 billion Around DKK 7.5 billion
    Depreciation, amortisation and impairment losses Around DKK 5.5 billion Around DKK 6 billion
    Free cash flow DKK 39-44 billion DKK 37-42 billion

    For 2021, sales growth is now expected to be 10% to 13% at CER. The guidance reflects expectations for continued sales growth in both International Operations and in North America Operations. The guidance reflects expectations for sales growth across therapy areas, mainly driven by Diabetes and Obesity care. Intensifying competition within both Diabetes care and Biopharm is also reflected in the guidance. Furthermore, continued pricing pressure within Diabetes care, especially in the US, is expected to negatively impact sales development. Given the current exchange rates versus the Danish krone, growth reported in DKK is still expected to be around 4 percentage points lower than at CER.

    Operating profit growth is now expected to be 9% to 12% at CER. The expectation for operating profit growth primarily reflects the sales growth outlook and continued investments in current and future growth drivers across the operating units, including the continued roll-out of Ozempic® and Rybelsus® as well as global investments in building the anti-obesity market and the launch of Wegovy™. Furthermore, resources are allocated to both early and late-stage pipeline activities, including expected initiations of several phase 3a clinical trial programmes in 2021. Given the current exchange rates versus the Danish krone, growth reported in DKK is now expected to be around 5 percentage points lower than at CER.

    The current COVID-19 pandemic causes uncertainty to the outlook regarding the number of patients initiating treatment and societal impacts such as the unemployment rate in the US, which is impacting healthcare insurance coverage. The outlook is based on a number of assumptions related to the severity and duration of impacts from COVID-19. Consequently, volatility in quarterly results should be expected.

    For 2021, Novo Nordisk now expects financial items (net) to amount to a gain of around DKK 0.6 billion, mainly reflecting gains associated with foreign exchange hedging contracts.

    El effective tax rate for 2021 is now expected to be in the range of 19-21%.

    Capital expenditure is still expected to be around DKK 7.5 billion in 2021.

    Depreciation, amortisation and impairment losses are now expected to be around DKK 5.5 billion reflecting phasing of depreciation of the new production facility for diabetes active pharmaceutical ingredients in Clayton, North Carolina, US.

    El free cash flow is now expected to be DKK 39-44 billion reflecting higher net profit expectations.

    All of the above expectations are based on assumptions that the global or regional macroeconomic and political environment will not significantly change business conditions for Novo Nordisk during 2021, including the potential

    Strategic aspirations Performance highlights Commercial execution Financials Cash flow and capital allocation Outlook Innovation and therapeutic focus Purpose and sustainability Financial Information
    Company announcement No 48 / 2021

    Financial report for the period 1 January 2021 to 30 June 2021

    implications from major healthcare reforms and legislative changes as well as outcome of legal cases, and that the currency exchange rates, especially the US dollar, will remain at the current level versus the Danish krone. Neither does the guidance include the financial implications of significant business development transactions during the remainder of 2021.

    FX Q2 2021 Q2 2020 % change H1 2021 H1 2020 % change Spot rate
    30 July 2021
    Dólar estadounidense 617 677 (9 %) 617 678 (9 %) 626
    CNY 96 96 0 % 95 96 (1 %) 97
    JPY 5.64 6.30 (10 %) 5.73 6.26 (8 %) 5.70
    CAD 502 489 3 % 495 497 0 % 503
    GBP 863 840 3 % 857 855 0 % 874

    Novo Nordisk has hedged expected net cash flows in a number of invoicing currencies and, all other things being equal, movements in key invoicing currencies will impact Novo Nordisk’s operating profit as outlined in the table below.

    Key invoicing currencies Impact on Novo Nordisk's operating profit in the next 12 months of a 5% movement in currency

    Hedging period (months)1

    Dólar estadounidense DKK 2,000 million 12

    CNY2

    DKK 470 million 0
    JPY DKK 210 million 12
    CAD DKK 160 million 9
    GBP DKK 120 million 11

    1) As of 30 July 2021.

    2) Chinese yuan traded offshore (CNH) used as proxy when hedging Novo Nordisk’s CNY currency exposure.

    The financial impact from foreign exchange hedging is included in Financial items (net).

    Strategic aspirations Performance highlights Commercial execution Financials Cash flow and capital allocation Outlook Innovation and therapeutic focus Purpose and sustainability Financial Information
    Company announcement No 48 / 2021

    Financial report for the period 1 January 2021 to 30 June 2021

    INNOVATION AND THERAPEUTIC FOCUS

    Diabetes care

    Resubmission of once-weekly semaglutide 2.0 mg for the treatment of type 2 diabetes for US regulatory approval

    On 28 May 2021, Novo Nordisk resubmitted a label expansion application to the US Food and Drug Administration (FDA) for Ozempic®, a once-weekly GLP-1 analogue, to introduce a new dose of 2.0 mg. The resubmission follows the Refusal to File letter received by the FDA on 22 March 2021. The standard review time by the FDA is ten months.

    Phase 2 trial initiated with cagrilintide in combination with semaglutide in people with type 2 diabetes

    In August 2021, Novo Nordisk initiated a 37-week phase 2 trial comparing the effect on glycaemic control and body weight of cagrilintide in combination with semaglutide compared to semaglutide in people with type 2 diabetes.

    Obesity care

    Wegovy™ (semaglutide 2.4 mg) approved in the US for weight management

    On 4 June 2021, Wegovy™, once-weekly subcutaneous semaglutide 2.4 mg, was approved by the FDA as an adjunct to diet and exercise for chronic weight management in adults living with obesity (BMI > 30 kg/m2) or overweight (BMI > 27 kg/m2) with at least one weight-related comorbidity. The approval is based on the results from the STEP phase 3a clinical trial programme. Across trials in people without type 2 diabetes, an average weight loss from a baseline of 17-18% sustained over 68 weeks was reported for people with obesity treated with Wegovy™ (based on the trial product estimand, secondary statistical approach: treatment effect if all people adhered to treatment and did not initiate other anti-obesity therapies. When using a treatment policy estimand, 15-17% weight loss was reported). Wegovy™ demonstrated a safe and well-tolerated profile across the programme, with the most common adverse events being gastrointestinal. Novo Nordisk launched Wegovy™ in the US in June 2021. For more information, please read the company announcement here: www.novonordisk.com/content/nncorp/global/en/news-and-media/news-and-ir-materials/news-details.html?id=62112 (the contents of the company's website do not form a part of this Form 6-K).

    Phase 3b trials STEP 5 and STEP 8 for Wegovy™ successfully completed

    In May and June 2021, Novo Nordisk successfully completed two phase 3b trials with Wegovy™ investigating weight loss after two years of treatment compared to placebo (STEP 5) and comparing the weight loss effect with Saxenda® and placebo (STEP 8) in people with obesity (BMI > 30 kg/m2) or overweight (BMI > 27 kg/m2) without type 2 diabetes. In STEP 5, participants treated with Wegovy™ achieved a statistically significant and superior body weight reduction compared to placebo (16.7% versus 0.6%) from baseline to week 104. In STEP 8, treatment with Wegovy™ resulted in a statistically significant body weight reduction of 17.1% compared to 6.6% for Saxenda® and 1.8% for placebo. Both Wegovy™ and Saxenda® appeared to have safe and well-tolerated profiles in the trials.

    Phase 2 trial initiated with PYY 1875 in people with obesity

    In July 2021, Novo Nordisk initiated a phase 2 proof of concept trial with PYY 1875 for weight management. The trial is investigating safety, tolerability, pharmacokinetics and pharmacodynamics of different doses of PYY 1875 in combination with semaglutide 2.4 mg compared to placebo. The 42-week trial is expected to enrol around 75 people with obesity.

    Other serious chronic diseases

    Phase 3 programme initiated with oral semaglutide 14 mg in Alzheimer’s Disease

    In May 2021, Novo Nordisk initiated two phase 3a trials, evoke and evoke+, investigating the efficacy and safety of oral semaglutide in early Alzheimer’s Disease (AD). The randomised, placebo-controlled trials assess efficacy and safety of oral semaglutide 14 mg in a total of 3,680 people with early AD (mild cognitive impairment and mild dementia). The duration of the trials is three years.

    Phase 2 trial initiated with oral PCSK9i

    In August 2021, Novo Nordisk initiated a phase 2 dose finding trial with a novel oral PCSK9i. The 12-week phase 2 trial is investigating efficacy, pharmacokinetics and safety of several doses of PCSK9i compared to evolucumab and placebo. The phase 2 trial is based on results from a phase 1 trial with a subcutaneous formulation of the PCSK9i and it is expected to enrol around 250 people with high LDL-cholesterol.

    Acquisition agreement for Prothena’s ATTR amyloidosis programme

    Strategic aspirations Performance highlights Commercial execution Financials Cash flow and capital allocation Outlook Innovation and therapeutic focus Purpose and sustainability Financial Information
    Company announcement No 48 / 2021

    Financial report for the period 1 January 2021 to 30 June 2021

    In July 2021, Novo Nordisk and Prothena Corporation plc signed a definitive purchase agreement under which Novo Nordisk has acquired Prothena’s clinical stage antibody PRX004 and broader ATTR amyloidosis (transthyretin) programme. Novo Nordisk will develop the phase 2-ready antibody PRX004 for the rare heart disease ATTR cardiomyopathy. Under the terms of the definitive purchase agreement, Novo Nordisk acquires Prothena’s wholly-owned subsidiary and gains full worldwide rights to the intellectual property and related rights of Prothena’s ATTR amyloidosis business and pipeline. Prothena is eligible to receive development and sales milestone payments totalling up to USD 1.2 billion including USD 100 million in upfront and near-term clinical milestone payments.

    Global collaboration and licence agreement with Heartseed for stem cell-based therapy for heart failure

    In June 2021, Novo Nordisk and Heartseed Inc. entered into an exclusive worldwide collaboration and licence agreement for development, manufacturing and commercialisation of Heartseed’s lead asset HS-001. HS-001 is an investigational cell therapy using purified cardiomyocytes derived from induced pluripotent stem cells (iPSC), which is currently under development by Heartseed for the treatment of heart failure. Heartseed will maintain the rights to solely develop HS-001 in Japan and Novo Nordisk has the rights to co-commercialise the product in Japan with Heartseed with 50/50 profit and cost sharing. Heartseed is eligible to receive payments totalling up to 598 million US dollars including 55 million dollars in upfront and near-term milestone payments.

    Purpose and sustainability

    Circular for Zero

    As part of the environmental strategy 'Circular for Zero', Novo Nordisk has a target of all direct suppliers supply Novo Nordisk using 100% renewable power by 2030. Since the launch of the target in September 2020, suppliers representing approximately 25% of supply chain carbon emissions have committed to use renewable power when supplying to Novo Nordisk. This change has already reduced Novo Nordisk's direct supply chain carbon emissions by more than 15%. Further, to reduce carbon emissions from travel, new guidelines to limit business travel and encourage online meetings are being implemented.

    Novo Nordisk carbon emissions from operations and transport decreased by 45% to 83,215 tons in the first six months of 2021 compared to the first six months of 2019. The decrease was driven by renewable energy projects and impacts from COVID-19 on travelling. 2019 is used as baseline as 2020 was impacted by the COVID-19 pandemic.

    Social

    Defeat Diabetes

    Novo Nordisk continues to take action under the social responsibility strategy ‘Defeat Diabetes’ with a keen focus on access and affordability and prevention. Within access and affordability, Novo Nordisk is expanding the Changing Diabetes® in Children partnership aspiring to reach 100,000 children and young people with type 1 diabetes in low-resource settings by 2030. Together with global partners – F. Hoffmann-La Roche AG, International Society for Paediatric and Adolescent Diabetes and the World Diabetes Foundation – Novo Nordisk is including new countries in the programme, most recently Ghana in June 2021. 15 countries are now included.

    Within prevention, Novo Nordisk launched the Prevention Accelerator in June, inviting start-ups developing digital solutions to submit ideas for how to enable individuals and societies to predict or prevent obesity. This initiative comes in addition to the Healthy Food Challenge, launched in January in partnership with the EAT Foundation. The Healthy Food Challenge invited community stakeholders and private businesses to prevent obesity through solutions that advance healthy and sustainable food environments for vulnerable people.

    Employees

    The number of full-time employees at the end of the first six months of 2021 increased by 3.3% compared to 12 months ago. The total number of employees was 46,574 corresponding to 45,971 full-time positions. The increase is driven by International Operations, Product Supply and R&D, partially countered by North America Operations.

    Strategic aspirations Performance highlights Commercial execution Financials Cash flow and capital allocation Outlook Innovation and therapeutic focus Purpose and sustainability Financial Information
    Company announcement No 48 / 2021

    Financial report for the period 1 January 2021 to 30 June 2021

    Diversity and inclusion

    Being a sustainable employer offering an inclusive and diverse working environment is an integrated part of being a sustainable business. While a number of initiatives have been launched to progress gender diversity in Novo Nordisk, only gradual progress has been made as the current share of women in senior leadership positions is 35% (defined as vice presidents, corporate vice presidents, senior vice presidents and executive vice presidents).

    To underline Novo Nordisk’s commitment, accelerate progress and ensure leadership accountability, Novo Nordisk has defined the following global aspirational targets:

    •Create an inclusive culture where all employees have a sense of belonging and equitable opportunities to realise their potential

    •Achieve a balanced gender representation across all managerial levels

    •Achieve a minimum of 45% women and a minimum of 45% men in senior leadership positions by the end of 2025

    Balanced is defined as the range between 45%-55% to leave up to 10% flexibility for women and men and also allow for non-binary gender recognising that some employees may not wish to be categorised.

    While gender is one dimension of diversity, Novo Nordisk fully recognises that diversity is any dimension that differentiates people and enables a diverse line of thought.

    Novo Nordisk’s Diversity and Inclusion policy can be found at novonordisk.com.

    Strategic aspirations Performance highlights Commercial execution Financials Cash flow and capital allocation Outlook Innovation and therapeutic focus Purpose and sustainability Financial Information
    Company announcement No 48 / 2021

    Financial report for the period 1 January 2021 to 30 June 2021

    MANAGEMENT STATEMENT

    The Board of Directors and Executive Management have reviewed and approved the financial report of Novo Nordisk A/S

    for the first six months of 2021. The financial report has not been audited or reviewed by the company’s

    independent auditors.

    The financial report for the first six months of 2021 has been prepared in accordance with IAS 34 'Interim Financial

    Reporting' and additional Danish disclosure requirements for listed companies. The accounting policies adopted in the preparation are consistent with those applied in the Annual Report 2020 of Novo Nordisk.

    In our opinion, the financial report for the first six months of 2021 gives a true and fair view of the Group’s assets, liabilities and financial position at 30 June 2021, and of the results of the Group’s operations and cash flow for the period 1 January 2021 to 30 June 2021. Furthermore, in our opinion, Management’s Review includes a true and fair account of the development in the operations and financial circumstances of the results for the period and of the financial position of the Group as well as a description of the most significant risks and elements of uncertainty facing the Group in accordance with Danish disclosure requirements for listed companies.

    Besides what has been disclosed in the quarterly financial report, no changes in the Group’s most significant risks and

    uncertainties have occurred relative to what was disclosed in the consolidated Annual Report 2020.

    Bagsværd, 4 August 2021

    Executive Management:

    Lars Fruergaard Jørgensen

    President and CEO

    Karsten Munk Knudsen

    CFO

    Monique Carter
    Martin Holst Lange Marcus Schindler Camilla Sylvest
    Henrik Wulff
    Board of Directors:

    Helge Lund

    Chair

    Jeppe Christiansen

    Vice chair

    Laurence Debroux
    Andreas Fibig Sylvie Grégoire Mette Bøjer Jensen
    Kasim Kutay Anne Marie Kverneland Martin Mackay
    Henrik Poulsen Thomas Rantzau Stig Strøbæk
    Strategic aspirations Performance highlights Commercial execution Financials Cash flow and capital allocation Outlook Innovation and therapeutic focus Purpose and sustainability Financial Information
    Company announcement No 48 / 2021

    Financial report for the period 1 January 2021 to 30 June 2021

    About Novo Nordisk

    Novo Nordisk is a leading global healthcare company, founded in 1923 and headquartered in Denmark. Our purpose is to drive change to defeat diabetes and other serious chronic diseases such as obesity and rare blood and endocrine disorders. We do so by pioneering scientific breakthroughs, expanding access to our medicines and working to prevent and ultimately cure disease. Novo Nordisk employs about 45,800 people in 80 countries and markets its products in around 170 countries. Novo Nordisk's B shares are listed on Nasdaq Copenhagen (Novo-B). Its ADRs are listed on the New York Stock Exchange (NVO). For more information, visit novonordisk.com, Facebook, Twitter, LinkedIn, YouTube.

    Financial calendar
    3 November 2021 Financial statement for the first nine months of 2021
    2 February 2022 Financial statement for 2021
    Contacts for further information
    Media:
    Mette Kruse Danielsen +45 3079 3883 mkd@novonordisk.com
    Michael Bachner (US) +1 609 664 7308 mzyb@novonordisk.com
    Investors:
    Daniel Muusmann Bohsen +45 3075 2175 dabo@novonordisk.com
    Ann Søndermølle Rendbæk +45 3075 2253 arnd@novonordisk.com
    David Heiberg Landsted +45 3077 2253 dhel@novonordisk.com
    Mark Joseph Root (US) +1 848 213 3219 mjhr@novonordisk.com

    Further information about Novo Nordisk is available on novonordisk.com.

    Forward-looking statements

    Novo Nordisk’s reports filed with or furnished to the US Securities and Exchange Commission (SEC), including this document as well as the company’s statutory Annual Report 2020 and Form 20-F both filed with the SEC in February 2021 in continuation of the publication of the Annual Report 2020, and written information released, or oral statements made, to the public in the future by or on behalf of Novo Nordisk, may contain forward-looking statements. Words such as ‘believe’, ‘expect’, ‘may’, ‘will’, ‘plan’, ‘strategy’, ‘prospect’, ‘foresee’, ‘estimate’, ‘project’, ‘anticipate’, ‘can’, ‘intend’, ‘target’ and other words and terms of similar meaning in connection with any discussion of future operating or financial performance identify forward-looking statements. Examples of such forward-looking statements include, but are not limited to:

    •statements of targets, plans, objectives or goals for future operations, including those related to Novo Nordisk’s products, product research, product development, product introductions and product approvals as well as cooperation in relation thereto,

    •statements containing projections of or targets for revenues, costs, income (or loss), earnings per share, capital expenditures, dividends, capital structure, net financials and other financial measures,

    •statements regarding future economic performance, future actions and outcome of contingencies such as legal proceedings, and

    •statements regarding the assumptions underlying or relating to such statements.

    In this document, examples of forward-looking statements can be found under the headings ‘Outlook’, ‘Research and Development update’ and 'Equity’.

    These statements are based on current plans, estimates and projections. By their very nature, forward-looking statements involve inherent risks and uncertainties, both general and specific. Novo Nordisk cautions that a number of important factors, including those described in this document, could cause actual results to differ materially from those contemplated in any forward-looking statements.

    Factors that may affect future results include, but are not limited to, global as well as local political and economic conditions, including interest rate and currency exchange rate fluctuations, delay or failure of projects related to research and/or development, unplanned loss of patents, interruptions of supplies and production, product recalls, unexpected contract breaches or terminations, government-mandated or market-driven price decreases for Novo Nordisk’s products, introduction of competing products, reliance on information technology, Novo Nordisk’s ability to successfully market current and new products, exposure to product liability and legal proceedings and investigations, changes in governmental laws and related interpretation thereof, including on reimbursement, intellectual property protection and regulatory controls on testing, approval, manufacturing and marketing, perceived or actual failure to adhere to ethical marketing practices, investments in and divestitures of domestic and foreign companies, unexpected growth in costs and expenses, failure to recruit and retain the right employees, failure to maintain a culture of compliance and epidemics, pandemics or other public health crises.

    For an overview of some, but not all, of the risks that could adversely affect Novo Nordisk’s results or the accuracy of forward-looking statements in this document, reference is made to the overview of risk factors in ‘Risk Management’ of the Annual Report 2020.

    Unless required by law, Novo Nordisk is under no duty and undertakes no obligation to update or revise any forward-looking statement after the distribution of this document, whether as a result of new information, future events or otherwise.

    Strategic aspirations Performance highlights Commercial execution Financials Cash flow and capital allocation Outlook Innovation and therapeutic focus Purpose and sustainability Financial Information
    Company announcement No 48 / 2021

    Financial report for the period 1 January 2021 to 30 June 2021

    APPENDIX 1: QUARTERLY NUMBERS IN DKK

    (Amounts in DKK million, except number of full-time equivalent employees, earnings per share and number of shares outstanding).
    % change
    2021 2020 Q2 2021 vs.
    Q2 Q1 Q4 Q3 Q2 Q1 Q2 2020
    Las ventas netas 33,041 33,804 32,138 30,927 30,006 33,875 10 %
    Gross profit 27,494 27,993 26,519 25,772 25,234 28,489 9 %
    Gross margin 83.2% 82.8% 82.5% 83.3% 84.1% 84.1%
    Sales and distribution costs 8,001 8,256 9,766 8,174 7,398 7,590 8 %
    Percentage of sales 24.2% 24.4% 30.4% 26.4% 24.7% 22.4%
    Research and development costs 3,944 3,944 4,483 3,911 3,291 3,777 20 %
    Percentage of sales 11.9% 11.7% 13.9% 12.6% 11.0% 11.1%
    Administrative costs 904 932 1,198 1,006 827 927 9 %
    Percentage of sales 2.7% 2.8% 3.7% 3.3% 2.8% 2.7%
    Other operating income, net 134 121 106 127 120 107 12 %
    Operating profit 14,779 14,982 11,178 12,808 13,838 16,302 7 %
    Operating margin 44.7% 44.3% 34.8% 41.4% 46.1% 48.1%
    Financial income 90 1,753 1,352 162 97 17 (7 %)
    Financial expenses (48) 797 528 279 519 1,298 (109 %)
    Financial items (net) 138 956 824 (117) (422) (1,281) (133 %)
    Profit before income taxes 14,917 15,938 12,002 12,691 13,416 15,021 11 %
    Income taxes 2,794 3,315 2,684 2,393 2,791 3,124 0 %
    Beneficio neto 12,123 12,623 9,318 10,298 10,625 11,897 14 %
    Depreciation, amortisation and
    impairment losses
    1,217 1,377 1,379 2,130 1,158 1,086 5 %
    Capital expenditure 1,709 1,402 1,518 1,401 1,239 1,667 38 %
    Net cash generated from operating activities 25,255 11,255 172 17,506 24,261 10,012 4 %
    Free cash flow 23,164 9,532 (12,994) 11,224 22,666 7,669 2 %
    Total assets 158,095 141,387 144,922 139,947 136,121 126,256 dieciséis %
    Total equity 65,559 58,496 63,325 59,573 60,054 54,399 9 %
    Equity ratio 41.5% 41.4% 43.7% 42.6% 44.1% 43.1%
    Full-time equivalent employees end of period 45,971 45,157 44,723 44,326 43,526 43,158 6 %
    Basic earnings per share/ADR (in DKK) 5.26 5.47 4.02 4.42 4.54 5.07 dieciséis %
    Diluted earnings per share/ADR (in DKK) 5.26 5.45 4.01 4.42 4.53 5.05 dieciséis %
    Average number of shares outstanding (million) 2,300.8 2,309.6 2,318.9 2,329 2,338.8 2,348.8 (2 %)
    Average number of diluted shares outstanding (million) 2,306.3 2,315.6 2,325.1 2,335.1 2,344.9 2,354.8 (2 %)
    Sales by business segment:
    Total GLP-1 12,077 11,300 11,780 10,651 9,425 9,975 28 %
    Long-acting insulin 4,149 4,822 5,013 4,048 4,220 5,158 (2 %)
    Premix insulin 2,715 2,953 2,705 2,572 2,693 2,955 1 %
    Fast-acting insulin 4,252 4,556 4,231 4,589 4,379 5,114 (3 %)
    Human insulin 2,041 2,535 1,678 2,194 2,314 2,687 (12 %)
    Total insulin 13,157 14,866 13,627 13,403 13,606 15,914 (3 %)
    Other Diabetes care 809 1,110 975 954 977 1,125 (17 %)
    Total Diabetes care 26,043 27,276 26,382 25,008 24,008 27,014 8 %

    Obesity care (Saxenda® and WegovyTM)

    1,992 1,551 1,385 1,338 1,308 1,577 52 %
    Diabetes and Obesity care total 28,035 28,827 27,767 26,346 25,316 28,591 11 %

    Rare blood disorders1)

    2,723 2,678 2,140 2,311 2,401 2,810 13 %

    Rare endocrine disorders1)

    1,859 1,920 1,833 1,891 1,952 2,031 (5 %)
    Other Biopharm 424 379 398 379 337 443 26 %
    Biopharm total 5,006 4,977 4,371 4,581 4,690 5,284 7 %
    Sales by geographic segment:
    International Operations 18,237 18,747 15,430 15,988 16,115 18,296 13 %
    – EMEA 9,579 9,530 8,138 8,318 8,167 9,674 17 %
    – Region China 3,722 4,330 3,248 3,549 3,474 3,813 7 %
    – Rest of World 4,936 4,887 4,044 4,121 4,474 4,809 10 %
    North America Operations 14,804 15,057 16,708 14,939 13,891 15,579 7 %
    – The US 13,754 14,172 15,877 14,144 13,028 14,775 6 %
    Segment operating profit:
    Diabetes and Obesity care 12,155 12,470 9,106 9,748 11,434 13,456 6 %
    Biopharm 2,624 2,512 2,072 3,060 2,404 2,846 9 %

    1) Comparative numbers have been restated as Macrillen (previously disclosed under Other biopharm) is now disclosed as part of Rare endocrine disorders.

    Strategic aspirations Performance highlights Commercial execution Financials Cash flow and capital allocation Outlook Innovation and therapeutic focus Purpose and sustainability Financial Information
    Company announcement No 48 / 2021

    Financial report for the period 1 January 2021 to 30 June 2021

    APPENDIX 2: INCOME STATEMENT AND STATEMENT OF COMPREHENSIVE INCOME

    DKK million H1 2021 H1 2020 Q2 2021 Q2 2020
    Income statement
    Las ventas netas 66,845 63,881 33,041 30,006
    Cost of goods sold 11,358 10,158 5,547 4,772
    Gross profit 55,487 53,723 27,494 25,234
    Sales and distribution costs 16,257 14,988 8,001 7,398
    Research and development costs 7,888 7,068 3,944 3,291
    Administrative costs 1,836 1,754 904 827
    Other operating income, net 255 227 134 120
    Operating profit 29,761 30,140 14,779 13,838
    Financial income 1,843 114 90 97
    Financial expenses 749 1,817 (48) 519
    Profit before income taxes 30,855 28,437 14,917 13,416
    Income taxes 6,109 5,915 2,794 2,791
    NET PROFIT 24,746 22,522 12,123 10,625
    Basic earnings per share (DKK) 10.73 9.61 5.26 4.54
    Diluted earnings per share (DKK) 10.71 9.58 5.26 4.53
    Segment Information
    Segment sales:
    Diabetes and Obesity care 56,862 53,907 28,035 25,316
    Biopharm 9,983 9,974 5,006 4,690
    Segment operating profit:
    Diabetes and Obesity care 24,625 24,890 12,155 11,434
    Operating margin 43.3% 46.2% 43.4% 45.2%
    Biopharm 5,136 5,250 2,624 2,404
    Operating margin 51.4% 52.6% 52.4% 51.3%
    Total segment operating profit 29,761 30,140 14,779 13,838
    Statement of comprehensive income
    Net profit for the period 24,746 22,522 12,123 10,625
    Other comprehensive income
    Items that will not subsequently be reclassified to the Income
    declaración
    Remeasurements on defined benefit plans 196 104 (17) (113)
    Items that will be reclassified subsequently to the Income
    declaración
    Exchange rate adjustments of investments in subsidiaries 529 (214) (74) (329)
    Cash flow hedges, realisation of previously deferred (gains)/losses (1,410) 408 (434) 97
    Cash flow hedges, deferred gains/(losses) incurred during the period (813) 413 760 994
    Other items (2) 3 – –
    Tax on other comprehensive income, income/(expense) 528 (343) (69) (265)
    Other comprehensive income for the period, net of tax (972) 371 166 384
    TOTAL COMPREHENSIVE INCOME FOR THE PERIOD 23,774 22,893 12,289 11,009
    Strategic aspirations Performance highlights Commercial execution Financials Cash flow and capital allocation Outlook Innovation and therapeutic focus Purpose and sustainability Financial Information
    Company announcement No 48 / 2021

    Financial report for the period 1 January 2021 to 30 June 2021

    APPENDIX 3: CASH FLOW STATEMENT

    DKK million H1 2021 H1 2020
    Beneficio neto 24,746 22,522
    Adjustment for non-cash items:
    Income taxes in the Income Statement 6,109 5,915
    Depreciation, amortisation and impairment losses 2,594 2,244
    Other non-cash items 9,172 9,139
    Change in working capital 1,739 (463)
    Interest received 43 37
    Interest paid (85) (116)
    Income taxes paid (7,808) (5,005)
    Net cash generated from operating activities 36,510 34,273
    Purchase of intangible assets (272) (184)
    Purchase of property, plant and equipment (3,111) (2,906)
    Proceeds from other financial assets 3 –
    Purchase of other financial assets (4) –
    Sale of marketable securities 768 –
    Purchase of marketable securities (3,755) –
    Investment in associated company – (392)
    Dividend received from associated company 4 9
    Net cash used in investing activities (6,367) (3,473)
    Purchase of treasury shares (8,400) (8,211)
    Dividends paid (13,496) (12,551)
    Proceeds from issue of bonds 9,657 –
    Repayment of borrowings (6,072) (428)
    Net cash used in financing activities (18,311) (21,190)
    NET CASH GENERATED FROM ACTIVITIES 11,832 9,610
    Cash and cash equivalents at the beginning of the year 12,226 15,411
    Exchange gain/(loss) on cash and cash equivalents 169 (170)
    Cash and cash equivalents at the end of the period 24,227 24,851
    Strategic aspirations Performance highlights Commercial execution Financials Cash flow and capital allocation Outlook Innovation and therapeutic focus Purpose and sustainability Financial Information
    Company announcement No 48 / 2021

    Financial report for the period 1 January 2021 to 30 June 2021

    APPENDIX 4: BALANCE SHEET

    DKK million 30 Jun 2021 31 Dec 2020
    ASSETS
    Intangible assets 20,272 20,657
    Property, plant and equipment 52,076 50,269
    Investments in associated companies 566 582
    Deferred income tax assets 6,349 5,865
    Other receivables and prepayments 413 674
    Other financial assets 1,273 1,066
    TOTAL NON-CURRENT ASSETS 80,949 79,113
    Inventories 18,822 18,536
    Trade receivables 26,098 27,734
    Tax receivables 344 289
    Other receivables and prepayments 3,781 4,161
    Marketable securities 2,987 –
    Derivative financial instruments 885 2,332
    Cash at bank 24,229 12,757
    TOTAL CURRENT ASSETS 77,146 65,809
    TOTAL ASSETS 158,095 144,922
    EQUITY AND LIABILITIES
    Share capital 462 470
    Treasury shares (3) (8)
    Retained earnings 67,179 63,774
    Other reserves (2,079) (911)
    TOTAL EQUITY 65,559 63,325
    Borrowings 12,463 2,897
    Deferred income tax liabilities 1,818 2,502
    Retirement benefit obligations 1,216 1,399
    Provisions 4,241 4,526
    Total non-current liabilities 19,738 11,324
    Borrowings 1,301 7,459
    Trade payables 7,616 5,717
    Tax payables 2,902 3,913
    Other liabilities 13,797 17,005
    Derivative financial instruments 794 1,365
    Provisions 46,388 34,814
    Total current liabilities 72,798 70,273
    TOTAL LIABILITIES 92,536 81,597
    TOTAL EQUITY AND LIABILITIES 158,095 144,922
    Strategic aspirations Performance highlights Commercial execution Financials Cash flow and capital allocation Outlook Innovation and therapeutic focus Purpose and sustainability Financial Information
    Company announcement No 48 / 2021

    Financial report for the period 1 January 2021 to 30 June 2021

    APPENDIX 5: EQUITY STATEMENT

    DKK million Share
    capital
    Treasury
    Comparte
    Retained
    earnings
    Other reserves Total
    H1 2021
    Balance at the beginning of the period 470 (8) 63,774 (911) 63,325
    Net profit for the period 24,746 24,746
    Other comprehensive income for the period 196 (1,168) (972)
    Total comprehensive income for the period 24,942 (1,168) 23,774
    Transactions with owners:
    Dividends (13,496) (13,496)
    Share-based payments 371 371
    Tax related to restricted stock units (15) (15)
    Purchase of treasury shares (3) (8,397) (8,400)
    Reduction of the B share capital (8) 8 –
    Balance at the end of the period 462 (3) 67,179 (2,079) 65,559
    DKK million Share
    capital
    Treasury
    Comparte
    Retained
    earnings
    Other reserves Total
    H1 2020
    Balance at the beginning of the period 480 (10) 57,817 (694) 57,593
    Net profit for the period 22,522 22,522
    Other comprehensive income for the period 104 267 371
    Total comprehensive income for the period 22,626 267 22,893
    Transactions with owners:
    Dividends (12,551) (12,551)
    Share-based payments 312 312
    Tax related to restricted stock units 18 18
    Purchase of treasury shares (3) (8,208) (8,211)
    Reduction of the B share capital (10) 10 –
    Balance at the end of the period 470 (3) 60,014 (427) 60,054
    Strategic aspirations Performance highlights Commercial execution Financials Cash flow and capital allocation Outlook Innovation and therapeutic focus Purpose and sustainability Financial Information
    Company announcement No 48 / 2021

    Financial report for the period 1 January 2021 to 30 June 2021

    APPENDIX 6: SALES SPLIT PER AREA

    Q2 2021 sales split per area
    DKK million Total International
    Operaciones
    EMEA Región
    porcelana
    Rest of
    Mundo
    North America
    Operaciones
    The US
    Diabetes and Obesity care segment

    Rybelsus®

    945 69 55 – 14 876 858
    % change at CER 192% – – – – 171% 170%

    Ozempic®

    7,435 2,095 1,609 47 439 5,340 4,937
    % change at CER 65% 207% 169% – 419% 41% 39%

    Victoza®

    3,697 1,826 977 383 466 1,871 1,791
    % change at CER (7%) 3% (10%) 38% 13% (15%) (15%)
    Total GLP-1 12,077 3,990 2,641 430 919 8,087 7,586
    % change at CER 37% 62% 56% 53% 85% 28% 27%
    Long-acting insulin 4,149 2,746 1,698 492 556 1,403 1,261
    % change at CER 3% 18% 15% 34% 17% (17%) (18%)

    Tresiba®

    2,192 1,344 745 258 341 848 737
    % change at CER 7% 29% 24% 159% 1% (15%) (18%)

    Xultophy®

    645 532 420 – 112 113 111
    % change at CER 16% 36% 17% – 230% (30%) (30%)

    Levemir®

    1,312 870 533 234 103 442 413
    % change at CER (7%) (2%) 4% (13%) (3%) (15%) (15%)
    Premix insulin 2,715 2,604 735 1,246 623 111 105
    % change at CER 5% 4% 3% 3% 9% 17% 20%

    Ryzodeg®

    421 421 90 80 251 – –
    % change at CER 33% 33% 29% – 6% – –

    NovoMix®

    2,294 2,183 645 1,166 372 111 105
    % change at CER 1% 0% 0% (3%) 11% 17% 20%
    Fast-acting insulin 4,252 2,714 1,617 549 548 1,538 1,429
    % change at CER 3% 8% 9% 7% 8% (6%) (6%)

    Fiasp®

    435 273 235 – 38 162 152
    % change at CER 58% 63% 54% – 156% 50% 53%

    NovoRapid®

    3,817 2,441 1,382 549 510 1,376 1,277
    % change at CER (1%) 5% 4% 7% 4% (10%) (11%)
    Human insulin 2,041 1,756 537 590 629 285 262
    % change at CER (9%) (7%) (2%) (15%) (4%) (17%) (17%)
    Total insulin 13,157 9,820 4,587 2,877 2,356 3,337 3,057
    % change at CER 1% 7% 9% 3% 7% (11%) (12%)

    Other Diabetes care1

    809 586 178 289 119 223 189
    % change at CER (14%) (12%) 9% (20%) (19%) (18%) (20%)
    Total Diabetes care 26,043 14,396 7,406 3,596 3,394 11,647 10,832
    % change at CER 15% 17% 22% 5% 19% 13% 12%

    Obesity care (Saxenda® and Wegovy™)

    1,992 782 468 9 305 1,210 1,115
    % change at CER 63% 83% 108% – 51% 53% 54%
    Diabetes and Obesity care total 28,035 15,178 7,874 3,605 3,699 12,857 11,947
    % change at CER 17% 19% 25% 5% 21% 15% 15%
    Biopharm segment

    Rare blood disorders2

    2,723 1,538 899 78 561 1,185 1,119
    % change at CER 20% 10% 4% 212% 10% 37% 43%
    Haemophilia A 623 488 338 19 131 135 129
    % change at CER 66% 67% 66% 0% 52% 63% 68%
    Haemophilia B 162 97 66 1 30 65 34
    % change at CER 43% 49% 78% – 10% 34% 95%

    NovoSeven®

    1,875 938 488 58 392 937 910
    % change at CER 10% (9%) (21%) 157% 1% 36% 40%

    Rare endocrine disorders3

    1,859 1,258 598 39 621 601 596
    % change at CER 2% 7% 4% 122% 6% (6%) (6%)

    Other Biopharm4

    424 263 208 – 55 161 92
    % change at CER 27% 12% 5% 0% 43% 59% 106%
    Biopharm total 5,006 3,059 1,705 117 1,237 1,947 1,807
    % change at CER 13% 8% 4% 174% 9% 21% 24%
    Total sales 33,041 18,237 9,579 3,722 4,936 14,804 13,754
    % change at CER 17% 17% 20% 7% 18% 16% 16%
    % change as reported 10% 13% 17% 7% 10% 7% 6%
    Share of growth 100% 55% 34% 5% 16% 45% 42%

    1) Primarily NovoNorm®, needles and GlucaGen® HypoKit®.

    2) Comprises NovoSeven®, NovoEight®, Refixia®, NovoThirteen® and Esperoct®.

    3) Primarily Norditropin®.

    4) Primarily Vagifem® and Activelle®.

    Strategic aspirations Performance highlights Commercial execution Financials Cash flow and capital allocation Outlook Innovation and therapeutic focus Purpose and sustainability Financial Information
    Company announcement No 48 / 2021

    Financial report for the period 1 January 2021 to 30 June 2021
    H1 2021 sales split per area
    DKK million Total International
    Operaciones
    EMEA Región
    porcelana
    Rest of
    Mundo
    North America
    Operaciones
    The US
    Diabetes and Obesity care segment

    Rybelsus®

    1,674 167 90 – 77 1,507 1,479
    % change at CER 213% – – – – 183% 181%

    Ozempic®

    14,097 3,778 2,957 62 759 10,319 9,611
    % change at CER 58% 145% 115% – 324% 41% 40%

    Victoza®

    7,606 3,582 1,914 771 897 4,024 3,868
    % change at CER (12%) (1%) (16%) 56% 5% (19%) (19%)
    Total GLP-1 23,377 7,527 4,961 833 1,733 15,850 14,958
    % change at CER 30% 46% 36% 68% 69% 24% 23%
    Long-acting insulin 8,971 5,602 3,470 1,007 1,125 3,369 3,103
    % change at CER 2% 14% 8% 41% 15% (13%) (14%)

    Tresiba®

    4,557 2,691 1,501 480 710 1,866 1,660
    % change at CER 5% 26% 18% – 3% (15%) (18%)

    Xultophy®

    1,326 1,071 867 1 203 255 251
    % change at CER 12% 25% 9% – 190% (21%) (21%)

    Levemir®

    3,088 1,840 1,102 526 212 1,248 1,192
    % change at CER (6%) (4%) (4%) (5%) (4%) (9%) (8%)
    Premix insulin 5,668 5,393 1,508 2,668 1,217 275 263
    % change at CER 5% 6% 1% 10% 4% 2% 3%

    Ryzodeg®

    841 841 209 115 517 – –
    % change at CER 34% 34% 36% – 13% – –

    NovoMix®

    4,827 4,552 1,299 2,553 700 275 263
    % change at CER 2% 1% (4%) 5% (2%) 2% 3%
    Fast-acting insulin 8,808 5,508 3,274 1,164 1,070 3,300 3,092
    % change at CER (1%) 4% 1% 12% 7% (8%) (9%)

    Fiasp®

    837 531 466 – 65 306 288
    % change at CER 30% 39% 31% – 141% 17% 18%

    NovoRapid®

    7,971 4,977 2,808 1,164 1,005 2,994 2,804
    % change at CER (4%) 1% (3%) 12% 3% (10%) (11%)
    Human insulin 4,576 3,837 1,110 1,360 1,367 739 696
    % change at CER (3%) (1%) (9%) (7%) 13% (11%) (10%)
    Total insulin 28,023 20,340 9,362 6,199 4,779 7,683 7,154
    % change at CER 1% 6% 2% 10% 10% (11%) (11%)

    Other Diabetes care1

    1,919 1,427 353 834 240 492 422
    % change at CER (5%) (3%) 0% 4% (23%) (8%) (9%)
    Total Diabetes care 53,319 29,294 14,676 7,866 6,752 24,025 22,534
    % change at CER 11% 13% 11% 13% 19% 9% 9%
    Obesity care (Saxenda® and Wegovy™) 3,543 1,497 839 dieciséis 642 2,046 1,874
    % change at CER 34% 44% 55% 325% 30% 27% 27%
    Diabetes and Obesity care total 56,862 30,791 15,515 7,882 7,394 26,071 24,408
    % change at CER 13% 15% 13% 13% 20% 11% 10%
    Biopharm segment

    Rare blood disorders2

    5,401 3,172 1,998 99 1,075 2,229 2,092
    % change at CER 11% 5% 10% (54%) 7% 19% 22%
    Haemophilia A 1,120 870 621 20 229 250 238
    % change at CER 39% 37% 31% 217% 49% 49% 52%
    Haemophilia B 309 189 130 1 58 120 54
    % change at CER 30% 34% 46% – 13% 24% 55%

    NovoSeven®

    3,855 2,075 1,223 78 774 1,780 1,728
    % change at CER 3% (6%) (1%) (62%) (1%) 16% 19%

    Rare endocrine disorders3

    3,779 2,479 1,160 69 1,250 1,300 1,291
    % change at CER 2% 4% 1% 141% 3% (2%) (2%)

    Other Biopharm4

    803 542 436 2 104 261 135
    % change at CER 5% (4%) (6%) (50%) 13% 27% 42%
    Biopharm total 9,983 6,193 3,594 170 2,429 3,790 3,518
    % change at CER 7% 4% 5% (30%) 5% 12% 13%
    Total sales 66,845 36,984 19,109 8,052 9,823 29,861 27,926
    % change at CER 12% 13% 11% 12% 16% 11% 10%
    % change as reported 5% 7% 7% 10% 6% 1% 0%
    Share of growth 100% 58% 27% 11% 20% 42% 39%

    1) Primarily NovoNorm®, needles and GlucaGen® HypoKit®.

    2) Comprises NovoSeven®, NovoEight®, Refixia®, NovoThirteen® and Esperoct®.

    3) Primarily Norditropin®.

    4) Primarily Vagifem® and Activelle®.

    Strategic aspirations Performance highlights Commercial execution Financials Cash flow and capital allocation Outlook Innovation and therapeutic focus Purpose and sustainability Financial Information
    Company announcement No 48 / 2021

    Financial report for the period 1 January 2021 to 30 June 2021

    APPENDIX 7: NON-IFRS FINANCIAL MEASURES (ADDITIONAL INFORMATION)

    In this Company Announcement, Novo Nordisk discloses certain financial measures of the Group’s financial performance, financial position and cash flows that reflect adjustments to the directly comparable measures calculated and presented in accordance with IFRS. These non-IFRS financial measures may not be defined and calculated by other companies in the same manner and may thus not be comparable with such measures. The non-IFRS financial measures presented in the Company Announcement are Sales and operating profit at CER, Free cash flow and Financial reserves.

    Sales and operating profit growth at CER

    'Growth at CER’ means that the effect of changes in exchange rates is excluded. It is defined as Net sales/Operating profit for the period measured at the average exchange rates for the same period prior year compared with Net sales/Operating profit for the same period prior year. Price adjustments within hyperinflation countries as defined in IAS 29 ‘Financial reporting in hyperinflation economies’ are excluded from the calculation to avoid growth at CER being artificially inflated.

    Growth at CER is considered to be relevant information for investors in order to understand the underlying development in sales and operating profit by adjusting for the impact of currency fluctuations.

    Sales at CER
    DKK million H1 2021 H1 2020 % change
    H1 2021 to
    H1 2020
    Q2 2021 Q2 2020 % change
    Q2 2021 to
    Q2 2020
    Las ventas netas 66,845 63,881 5 % 33,041 30,006 10 %
    Effect of exchange rates 4,532 – 1,946 –
    Sales at CER 71,377 63,881 12 % 34,987 30,006 17 %
    Operating profit at CER
    DKK million H1 2021 H1 2020 % change
    H1 2021 to
    H1 2020
    Q2 2021 Q2 2020 % change
    Q2 2021 to
    Q2 2020
    Operating profit 29,761 30,140 (1 %) 14,779 13,838 7 %
    Effect of exchange rates 2,986 – 1,235 –
    Operating profit at CER 32,747 30,140 9 % 16,014 13,838 dieciséis %

    Free cash flow

    Novo Nordisk defines free cash flow as ’net cash generated from operating activities’, less ‘net cash used in investing activities’, less repayment on lease liabilities and excluding net change of marketable securities. Free cash flow is a measure of the amount of cash generated in the period which is available for the Board of Directors to allocate between Novo Nordisk's capital providers, through eg dividends, share repurchases and repayment of debt (excluding lease liability repayments) or for retaining in the business to fund future growth.

    The following table shows a reconciliation of Free cash flow with Net cash generated from operating activities, the most directly comparable IFRS financial measure:

    Free cash flow
    DKK million H1 2021 H1 2020 Q2 2021 Q2 2020
    Net cash generated from operating activities 36,510 34,273 25,255 24,261
    Net cash used in investing activities (6,367) (3,473) (2,886) (1,367)
    Repayment on lease liabilities (434) (465) (209) (228)
    Net change in marketable securities 2,987 – 1,004 –
    Free cash flow 32,696 30,335 23,164 22,666
    Strategic aspirations Performance highlights Commercial execution Financials Cash flow and capital allocation Outlook Innovation and therapeutic focus Purpose and sustainability Financial Information
    Company announcement No 48 / 2021

    Financial report for the period 1 January 2021 to 30 June 2021

    Financial reserves

    'Financial reserves' is defined as the sum of cash and cash equivalents at the end of the period, marketable securities with original term to maturity exceeding three months and undrawn committed credit and loan facilities, with a maturity of more than 12 months, less loans and bank overdrafts classified as liabilities arising from financing activities with obliged repayment within 12 months of the balance sheet date. The following table reconciles total financial reserves with cash and cash equivalents, the most directly comparable IFRS financial measure:

    Financial reserves
    DKK million H1 2021 H1 2020
    Cash and cash equivalents 24,227 24,851
    Marketable securities 2,987 –
    Undrawn committed credit facility 11,526 11,552
    Borrowings (525) (585)
    Financial reserves 38,215 35,818
    Strategic aspirations Performance highlights Commercial execution Financials Cash flow and capital allocation Outlook Innovation and therapeutic focus Purpose and sustainability Financial Information
    Company announcement No 48 / 2021

    SIGNATURES

    Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf of the undersigned, thereunto duly authorized.

    Date: August 4, 2021

    Novo Nordisk A/S

    Lars Fruergaard Jørgensen

    Chief Executive Officer

    Fuente

    Descargo de responsabilidad

    Toda la información contenida en este sitio web se publica solo con fines de información general y no como un consejo de inversión. Cualquier acción que el lector realice sobre la información que se encuentra en nuestro sitio web es estrictamente bajo su propio riesgo. Nuestra prioridad es brindar información de alta calidad. Nos tomamos nuestro tiempo para identificar, investigar y crear contenido educativo que sea útil para nuestros lectores. Para mantener este estándar y continuar creando contenido de buena calidad. Pero nuestros lectores pueden basarse en su propia investigación.

    Share. Facebook Twitter Pinterest LinkedIn WhatsApp Reddit Tumblr Email

    Related Posts

    Rublos Rusos a Pesos Mexicanos

    Rublos Rusos a Pesos Mexicanos ¿Cuánto vale 1 Rublo a Peso en moneda Rusa?

    octubre 2, 2022
    Big News Network

    Tipos de cambio del mercado en China – 24 de septiembre

    septiembre 24, 2021
    Oracle anuncia los resultados financieros del primer trimestre del año fiscal 2022 | Noticias

    Oracle anuncia los resultados financieros del primer trimestre del año fiscal 2022 | Noticias

    septiembre 14, 2021

    Leave A Reply Cancel Reply

    Siguenos
    • Facebook
    • Twitter
    También te puede intersar
    Qué es ChatGPT y cómo funciona Tecnología

    ¿Qué es ChatGPT y cómo funciona? ¿Qué la distingue a de otras herramientas de mensajería?

    ChatGPT: Los días en que la inteligencia artificial se comunica contigo de forma natural y…

    Biswap Ingresos pasivos

    Biswap Ingresos pasivos y clave para funciones lucrativas

    Liquidez

    Liquidez, ¿Qué significa?, Liquidez vs Volumen

    Carteras de Custodia

    Carteras de Custodia, ¿Qué Son?, Ventajas, Desventajas

    Type above and press Enter to search. Press Esc to cancel.